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Background: Central nervous system (CNS) complications are among the most common, devastating
sequelae of sickle cell disease (SCD) occurring throughout the lifespan.
Objective: These evidence-based guidelines of the American Society of Hematology are intended to
support the SCD community in decisions about prevention, diagnosis, and treatment of the most
common neurological morbidities in SCD.
Methods: The Mayo Evidence-Based Practice Research Program supported the guideline development
process, including updating or performing systematic evidence reviews. The panel used the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE
evidence-to-decision frameworks, to assess evidence and make recommendations.
Results: The panel placed a higher value on maintaining cognitive function than on being alive with
significantly less than baseline cognitive function. The panel developed 19 recommendations with
evidence-based strategies to prevent, diagnose, and treat CNS complications of SCD in low-middle–
and high-income settings.
Conclusions: Three of 19 recommendations immediately impact clinical care. These recommendations
include: use of transcranial Doppler ultrasound screening and hydroxyurea for primary stroke prevention in
children with hemoglobin SS (HbSS) and hemoglobin Sb0 (HbSb0) thalassemia living in low-middle–income
settings; surveillance for developmental delay, cognitive impairments, and neurodevelopmental disorders in
children; and use of magnetic resonance imaging of the brain without sedation to detect silent cerebral
infarcts at least once in early-school-age children and once in adults with HbSS or HbSb0 thalassemia.
Individuals with SCD, their family members, and clinicians should become aware of and implement these
recommendations to reduce the burden of CNS complications in children and adults with SCD.
Summary of recommendations
Background
Stroke, silent cerebral infarcts (silent strokes), and cognitive morbidity are the most common permanent
sequelae of sickle cell disease (SCD) in children and adults. Prior to 1990 in the United States, a large
prospective cohort study demonstrated that by 40 years of age, ;20% and ;10% of adults with
phenotype hemoglobin SS (HbSS) or hemoglobin SC (HbSC) had a cerebrovascular accident,
respectively (Figure 1).1 Over the last decades, screening with transcranial Doppler ultrasound (TCD)
Submitted 28 October 2019; accepted 3 February 2020; published online 16 April
2020. DOI 10.1182/bloodadvances.2019001142.
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and treatment with regular blood transfusion in children with
abnormal TCD velocities may result in a 10-fold decrease in the
prevalence of strokes in children with HbSS and hemoglobin Sb0
(HbSb0) thalassemia living in high-income settings.2
The most common cause of permanent neurological injury in
children and adults with HbSS and HbSb0 thalassemia is a silent
cerebral infarct, occurring in ;39% of children by 18 years3 of age
and .50% of adults by 30 years of age (Figure 2).4 Silent cerebral
infarcts require magnetic resonance imaging (MRI) to detect and a
formal neurological examination to exclude the presence of an overt
stroke.5 Both stroke and silent cerebral infarcts are associated with
significant cognitive impairments6 that may significantly alter
educational attainment, employment status, and quality of life.
One of the panel’s chief objectives was to establish guidelines
applicable to the .95% of children born with HbSS and HbSb0
thalassemia in low-middle–income countries. Conservatively, ,5%
of all children born in the world with HbSS or HbSb0 thalassemia
live in the United States and Europe.7 This estimate is based on the
consensus that there are;300 000 children annually born with HbSS
or HbSb0 thalassemia in the world,7 coupled with the evidence that
there are a total of 1971, 334, and 353 infants born with SCD per year
in the United States, United Kingdom, and France, respectively.8-10
Children and adults with HbSS living in low-middle–income settings
without resources to implement evidence-based strategies for primary
and secondary stroke prevention have high lifetime stroke risk,11 a risk
similar to that documented in the 1990s among children with HbSS in
high-income settings prior to the implementation of TCD screening and
regular blood transfusion therapy.1
The panel recognized that most of the recommendations would be
difficult to implement in low-middle–income settings where the majority
of children and adults with SCD live; however, when applicable, the
panel provided recommendations for these regions based on the best
available evidence. Major barriers to transferring knowledge about
neurological injury prevention from high-income to low-middle–income
settings include the low number of TCDmachines andMRI scanners to
detect central nervous system (CNS) pathology; the lack of sufficiently
trained health care providers to perform TCD; the low number of
physicians with expertise in hematology, neurology, and neuroradiology;
and access to therapy for primary and secondary stroke prevention.
Given the high prevalence of neurological morbidity in children and
adults with SCD, a critical component of the recommendations
includes involving individuals with SCD and their families in medical
decision-making. Families must be informed of (1) the presence of
neurological morbidity as diagnosed through imaging, cognitive testing,
or both; (2) the increased risk for future neurological morbidity; and (3)
plausible disease-modifying therapies that may attenuate or abate risks
of further neurological injury without data from phase 3 randomized
controlled trials. The panel developed 19 recommendations with
evidence-based strategies to prevent, screen, and treat CNS
complications of SCD in low-middle– and high-income settings.
These guidelines are based on original and updated systematic
reviews of evidence conducted under the direction of the Mayo
Evidence-Based Practice Research Program. The panel followed best
practices for guideline development recommended by the Institute of
Medicine and the Guidelines International Network (GIN).12-15 The
panel used the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) approach16-21 to assess the certainty
in the evidence and formulate recommendations.
Interpretation of strong and
conditional recommendations
The strength of a recommendation is expressed as either strong
(“the guideline panel recommends…”) or conditional (“the guideline
panel suggests…”) and has the following interpretation:
Strong recommendation
c For patients: Most individuals in this situation would want the
recommended course of action, and only a small proportion
would not.
c For clinicians: Most individuals should follow the recommended
course of action. Formal decision aids are not likely to be needed
to help individual patients make decisions consistent with their
values and preferences.
c For policy makers: The recommendation can be adopted as
policy in most situations. Adherence to this recommendation
according to the guideline could be used as a quality criterion or
performance indicator.
c For researchers: The recommendation is supported by credible
research or other convincing judgments that make additional
research unlikely to alter the recommendation. On occasion, a
strong recommendation is based on low or very low certainty in
the evidence. In such instances, further research may provide
important information that alters the recommendations.
Conditional recommendation
c For patients: The majority of individuals in this situation would
want the suggested course of action, but many would not.
Decision aids may be useful in helping patients to make
decisions consistent with their individual risks, values, and
preferences.
c For clinicians: Different choices will be appropriate for individual
patients, and clinicians must help each patient arrive at a
management decision consistent with the patient’s values and
preferences. Decision aids may be useful in helping individuals
make decisions consistent with their individual risks, values, and
preferences.
c For policy makers: Policy-making will require substantial debate
and involvement of various stakeholders. Performance measures
about the suggested course of action should focus on whether
an appropriate decision-making process is duly documented.
c For researchers: This recommendation is likely to be strength-
ened (for future updates or adaptation) by additional research.
An evaluation of the conditions and criteria (and the related
judgments, research evidence, and additional considerations)
that determined the conditional (rather than strong) recommen-
dation will help identify possible research gaps.
Interpretation of good practice statements
As described by the GRADE Guidance Group, good practice
statements endorse interventions or practices that the guide-
line panel agreed have unequivocal net benefit yet may not be
widely recognized or used.22 Good practice statements in these
guidelines are not based on a systematic review of available
evidence. Nevertheless, they may be interpreted as strong
recommendations.
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Recommendations
Primary stroke prevention for children with SCD living
in low-middle– and high-income settings
Recommendation 1.1. For children with HbSS or HbSb0
thalassemia (ages 2-16 years), the American Society of Hematol-
ogy (ASH) guideline panel recommends annual TCD screening
(strong recommendation based on moderate certainty in the
evidence about effects ÅÅÅ◯).
Recommendation 1.2. For children who have compound
heterozygous SCD other than HbSC and have evidence of hemolysis
in the same range as those with HbSS, the ASH guideline panel
suggests TCD screening (conditional recommendation based on
very low certainty in the evidence about effects Å◯◯◯).
Recommendation 2.1. For children with HbSS or HbSb0
thalassemia (ages 2-16 years) who have abnormal TCD velocities
and live in a high-income setting (where regular blood transfusion
therapy, typically every 3-4 weeks, is feasible to maintain the
maximum HbS level,30% and maintain the hemoglobin level.9.0
g/dL), the ASH guideline panel recommends regular blood trans-
fusion for at least a year (vs no transfusion) with the goal of keeping
maximum HbS levels below 30% and maintaining hemoglobin levels
.9.0 g/dL to reduce the risk of stroke (strong recommendation
based on moderate certainty in the evidence about effects ÅÅÅ◯).
Recommendation 2.2. For children who have compound
heterozygous SCD other than HbSC, who have evidence of
hemolysis in the same range as those with HbSS, an abnormal TCD
velocity, and live in a high-income setting (where regular blood
transfusion therapy is feasible), the ASH guideline panel suggests
regular blood transfusion for at least a year (vs no transfusion) with
the goal of keeping maximum HbS levels below 30% to reduce the
risk of stroke (conditional recommendation based on very low
certainty in the evidence about effects Å◯◯◯).
Recommendation 2.3. For children with SCD (ages 2-16 years)
and abnormal TCD results who have been receiving transfusion
therapy for at least 1 year and are interested in stopping transfusion,
according to the clinical trial risk stratification with an MRI and
magnetic resonance angiography (MRA) of the brain (see Technical
remarks in supplemental File 5), the ASH guideline panel suggests
that hydroxyurea treatment at the maximum tolerated dose can be
considered to substitute for regular blood transfusions (conditional
recommendation based on low certainty in the evidence about
effects ÅÅ◯◯).
Recommendation 3. For children (ages 2-16 years) with HbSS,
HbSb0 thalassemia, or compound heterozygous SCD who have
abnormal TCD screening and live in low-middle-income settings
(where regular blood transfusion therapy and chelation therapy are
not available or affordable), the ASH guideline panel suggests
hydroxyurea therapy with at least 20 mg/kg per day at a fixed dose
or the maximum tolerated dose (conditional recommendation based
on low certainty in the evidence about effects ÅÅ◯◯).
Acute and timely treatment of suspected or confirmed
ischemic stroke or TIA
Recommendation 4.1. For children or adults with SCD and
acute neurological deficits, including transient ischemic attack
(TIA), the ASH guideline panel recommends prompt blood
transfusion. The transfusion should be given immediately upon
recognition of symptoms without delay beyond 2 hours of acute
neurological symptom presentation. The type of transfusion (simple,
modified exchange, or apheresis) is dependent on individual patient
factors and local transfusion resources (strong recommendation
based on high certainty in the evidence about effects ÅÅÅÅ).
Recommendation 4.2. For children or adults with SCD and
acute neurological deficits including TIA, the ASH guideline panel
suggests exchange transfusion vs simple transfusion. When exchange
transfusion is not available within 2 hours of presentation for medical
care and hemoglobin is#8.5 g/dL, simple transfusion can be performed
to avoid delays in treatment while a manual exchange transfusion or an
automated apheresis is planned (conditional recommendation based on
low certainty in the evidence about effects ÅÅ◯◯).
Secondary prevention of ischemic strokes in children
and adults with HbSS or HbSb0 thalassemia
Recommendation 5. For children with HbSS or HbSb0
thalassemia and a history of prior ischemic stroke, the ASH
guideline panel recommends blood transfusion goals for secondary
stroke prevention of increasing the hemoglobin above 9 g/dL at all
times and maintaining the HbS level at ,30% of total hemoglobin
until the time of the next transfusion (strong recommendation based
on low certainty in the evidence about effects ÅÅ◯◯).
Recommendation 6. For adults and children with SCD,
moyamoya syndrome, and a history of stroke or TIA, the ASH
guideline panel suggests evaluation for revascularization surgery in
addition to regular blood transfusion (conditional recommendation
based on very low certainty in the evidence about effects ÅÅÅ◯).
Acute management of ischemic strokes and the
use of tPA for adults with SCD presenting with
stroke symptoms
Recommendation 7. For adults with SCD presenting with
symptoms of acute ischemic stroke who are being evaluated for IV
tissue plasminogen activator (tPA; age $18 years, no hemorrhage
on computed tomography [CT] scan, within 4.5 hours of onset of
symptoms/signs and without contraindications for thrombolysis),
the ASH guideline panel suggests management using a shared
decision-making approach that follows these principles:
1. For all patients, the administration of tPA should not delay
prompt simple or exchange blood transfusion therapy.
2. Patients may be considered for IV tPA based on its established
inclusion and exclusion criteria detailed in stroke management
algorithms.
3. The following factors suggest likely benefit from IV tPA: older
age, atrial fibrillation, diabetes, hypertension, and hyperlipidemia.
Management of younger patients without these risk factors
should emphasize early transfusion.
4. There are no validated risk stratification or reliable age cutoff
criteria to guide the choice of initial therapy. IV tPA is not
recommended for children with SCD (,18 years of age).
5. IV tPA is not recommended for children with SCD (,18 years of
age).
(Conditional recommendation based on very low certainty in the
evidence about effects Å◯◯◯).
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Screening for developmental delay or cognitive
impairment in children and adults with SCD
Recommendation 8.1. Given the high prevalence of develop-
mental delay and cognitive impairments in children with SCD,
coupled with the guidelines set by the American Academy of
Pediatrics, the ASH guideline panel recommends that clinicians
supervising care of children with SCD conduct surveillance using
simplified signaling questions for the following:
1. Concerns about developmental delays in preschool-age
children.
2. Concerns about neurodevelopmental disorders in school-age
children with SCD, such as academic or behavioral problems or
symptoms of inattention, hyperactivity, or impulsivity.
(Strong recommendation based on low certainty in the evidence
about effects ÅÅ◯◯).
Recommendation 8.2. For children with SCD who have
abnormal surveillance results suggesting increased risk for de-
velopmental delay or cognitive impairment, the ASH guideline panel
recommends screening or referral for formal screening by a
psychologist or a pediatrician able to perform screening with the
available validated tools (strong recommendation based on low
certainty in the evidence about effects ÅÅ◯◯).
Recommendation 8.3. Given the high prevalence of cognitive
impairment in adults with SCD, coupled with the guidelines set by
the American Academy of Neurology, the ASH guideline panel
recommends that clinicians supervising care of adults with SCD
conduct surveillance for cognitive impairment using simplified
signaling questions (strong recommendation based on low certainty
in the evidence about effects ÅÅ◯◯).
Recommendation 8.4. For adults who have abnormal surveil-
lance results suggesting cognitive impairment, the ASH guideline
panel recommends formal referral to a psychologist or a primary
care physician able to perform more in-depth cognitive evaluation
(strong recommendation based on low certainty in the evidence
about effects ÅÅ◯◯).
Cognitive rehabilitative strategy for children and
adults with cognitive impairments
Recommendation 9.1. For children with SCD and abnormal
screening for developmental or cognitive status, the ASH guideline
panel recommends the following:
1. A developmental, cognitive, and medical evaluation to diagnose
any related disorders and to identify modifiable risk factors for
developmental delays or cognitive impairments.
2. Following the cognitive domain-specific evidence-based guide-
lines for these conditions to provide appropriate interventions.
(Strong recommendation based on high certainty in the evidence
about effects ÅÅÅÅ).
Recommendation 9.2. For adults with SCD and abnormal
screening for cognitive status, the ASH guideline panel recom-
mends the following:
1. Cognitive and medical evaluation to diagnose any related
disorders and to identify modifiable risk factors for cognitive
impairments.
2. Following the cognitive domain-specific evidence-based guide-
lines for these conditions to provide appropriate interventions.
(Strong recommendation based on high certainty in the evidence
about effects ÅÅÅÅ).
Screening for silent cerebral infarcts in children and
adults with HbSS or HbSb0 thalassemia
Recommendation 10.1. Given the high prevalence of silent
cerebral infarcts in children with HbSS or HbSb0 thalassemia (1 in
3), and their association with cognitive impairment, poor school
performance, and future cerebral infarcts, the ASH guideline panel
recommends at least a 1-time MRI screening, without sedation,
to detect silent cerebral infarcts in early-school-age children,
when MRI can commonly be performed without sedation (strong
recommendation based on moderate certainty in the evidence
about effects ÅÅÅ◯).
Recommendation 10.2. Given the high prevalence of silent
cerebral infarcts in adults with HbSS or HbSb0 thalassemia (1 in 2)
and their association with cognitive impairment, poor school
performance, and future cerebral infarcts, the ASH guideline panel
suggests at least a 1-time MRI screening without sedation to detect
silent cerebral infarcts in adults with HbSS or HbSb0 thalassemia
(conditional recommendation based on low certainty in the evidence
about effects ÅÅ◯◯).
Values and preferences
Overall, the ASH Guideline Panel on Cerebrovascular Disease placed
a higher value on maintaining cognitive function than on being alive
with reduced cognitive function (significantly less than baseline
functioning). Given the high prevalence of neurological morbidity
(strokes, silent cerebral infarcts, and cognitive impairment) in children
and adults with SCD, a critical component of the recommenda-
tions includes involving the individual with SCD and the individual’s
family in care decisions. All panel members strongly believed that full
disclosures should occur with families regarding the cumulative high
risk of neurological morbidity in SCD, the utility of screening for
neurological disease (abnormal TCD, silent cerebral infarcts, cognitive
impairment), and biologically plausible therapies that may attenuate
future neurological injury without a phase 3 randomized controlled trial.
Explanations and other considerations
These recommendations take into consideration acceptability,
feasibility, cost-effectiveness, and impact on health equity. When
developing these recommendations, the ASH guideline panel
acknowledged variability in knowledge about risks and benefits of
treatments, as well as variability for patients, their family members,
and provider perceptions of the balance between harms vs benefits.
Good practice statements
Good practice statement 1. To adopt a health care system
strategy for tracking TCD assessments and treatment of children with
SCD and abnormal TCDmeasurements because these children are at
extremely high risk for ischemic strokes. Tracking TCD surveillance and
treatment in both low-middle– and high-income settings will signif-
icantly decrease strokes in children with SCD.
Good practice statement 2. To consult with a neurologist and
neuroradiologist (when available) for evaluation in all suspected
acute neurological events and neuroimaging studies. For suspected
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ischemic strokes, timely and appropriate red blood cell trans-
fusion (within 2 hours of presentation to medical care) should be
provided.
Good practice statement 3. To adopt a multidisciplinary (ie,
hematology, neurology, neurosurgery, and neuroradiology) team
management approach when a neurosurgical revascularization
procedure is being considered for SCD-related moyamoya syn-
drome as adjunctive therapy to regular blood transfusion therapy
for secondary stroke prevention.
Good practice statement 4. To inform children and adults
with HbSS and HbSb0 thalassemia and their families about the
affected individual’s silent cerebral infarct status based on at least 1
MRI of the brain without sedation, coupled with discussion about
potential disease-modifying therapy to prevent infarct recurrence.
Good practice statement 5. To have ongoing standardized
cognitive or behavior surveillance and, when impairments are identified,
refer the patient to a specialist who may better evaluate the magnitude
of the cognitive impairments and provide rehabilitative approaches.
Introduction
Aims of these guidelines and specific objectives
The purpose of these guidelines is to provide evidence-based
recommendations to facilitate prevention, diagnosis, and treatment
of neurological morbidity, including strokes, silent cerebral infarcts,
and cognitive morbidity, in children and adults with SCD. To achieve
this goal, the panel reviewed and critically appraised the literature
and provided evidence-based recommendations. Through im-
proved provider and patient education using evidence-based
recommendations, these guidelines aim to provide support for
shared decision-making between providers, patients, and their
families, which will result in decreased neurological morbidity and
mortality of children and adults with SCD.
The target audience includes patients, hematologists, general
practitioners, internists, other clinicians, and decision makers.
Policy makers interested in these guidelines include those involved
in developing local, national, or international plans with the goal of
improving access to evidence-based care. Local or national panels
may also use this document as a basis for implementation of
strategies to prevent neurological morbidity in children and adults
with SCD in their health care system. When health care systems
and health care providers adopt these guidelines, there will be a
decrease in neurological morbidity in children and adults with SCD.
Description of the health problem
Stroke, silent cerebral infarcts, and cognitive morbidity are the most
common permanent sequelae of SCD in children and adults. Prior
to 1990 in the United States, a large prospective cohort study
demonstrated that by 40 years of age,;20% and;10% of adults with
phenotypeHbSSorHbSChad a cerebrovascular accident, respectively
(Figure 1).1 For most children with HbSS living in low-middle–income
settings, ;11% will have a stroke by 18 years of age.1
The most common cause of permanent neurological injury in HbSS
or HbSb0 thalassemia is silent cerebral infarcts, occurring in;39%
of children3 and.50% of adults4 (Figure 2). Silent cerebral infarcts
require MRI to detect and a formal neurological examination to
exclude the presence of an overt stroke. Both stroke and silent
cerebral infarcts are associated with significant risk of infarct
recurrence and clinically relevant cognitive impairments, which may
indirectly alter employment status and quality of life.
In 2013, the American Heart Association/American Stroke
Association (AHA/ASA) for the first time endorsed a definition of
stroke that includes silent cerebral infarctions and silent cerebral
hemorrhages typically identified by MRI of the brain.23 This change
in definition reflects a shift in emphasis toward a radiological
demonstration (tissue-based definition) of infarction or hemorrhage
because permanent neurological injury may occur despite symp-
toms resolving in ,24 hours. For patients with cerebral ischemia,
the AHA/ASA stated that treatment should address the cause of
the ischemic event and not be governed only by whether infarction
has developed (in the case of TIA) or the size of the infarct.
The traditional definition of stroke endorsed by the World Health
Organization (WHO) requires clinical symptoms for.24 hours and
has been in use since the 1970s.24 Our panel affirmed the
importance of silent cerebral infarcts given the known impact on
cognition and an established biomarker for infarct recurrence in
children and adults with HbSS or HbSb0 thalassemia25-27 and
in the general population.28 However, we recognize that the
MRI-based definition is challenging in low-middle–income settings
where MRI is not widely available. Hence, the WHO definition of
stroke is clinically relevant29 and generalizable to individuals living in
both low-middle– and high-income settings.
Methods
The methodology of this guideline is published in detail elsewhere.30
The guideline panel developed and graded the recommendations
and assessed the certainty of the supporting evidence following the
GRADE approach.16-22,31 The overall guideline development pro-
cess, including funding of the work, panel formation, management
of conflicts of interest, internal and external review, and organiza-
tional approval, was guided by ASH policies and procedures
derived from the GIN–McMaster Guideline Development Checklist
(http://cebgrade.mcmaster.ca/guidecheck.html) and was intended
to meet recommendations for trustworthy guidelines by the Institute
of Medicine and the GIN.12-15
The Mayo Evidence-Based Practice Research Program conducted
or updated systematic reviews based on clinical questions de-
veloped and defined by the ASH guideline panel. This was a
multidisciplinary group and included multiple stakeholders (4
hematologists who provide medical care for children and adults
with SCD, 3 neurologists who provide medical care for children, 2
neuroradiologists who review the neuroimaging of children and
adults with SCD, a pediatric psychologist with expertise in SCD, an
individual with SCDwho has had a stroke, a parent of a child with SCD
who had a stroke after she was not offered TCD screening, and a
physician with expertise in evidence-based medicine methodology).
Following the GRADE approach, randomized trials and observational
studies provide an initial level of certainty in evidence classified as either
high or low, and this classificationmay be subsequently modified based
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on additional factors.32 Then, evidence-to-decision (EtD) factors are
applied to make a recommendation.
Recommendations are either strong or conditional. Strong recommen-
dations imply a high certainty of net benefit, such that the recommended
action should be applied to most patients as a standard of care.
Conditional recommendations imply that the balance of benefits and
harms is less clear. Although the recommended action should be offered
to the majority of patients, there will be important variation in context,
and, in some cases, an alternative action is reasonable.32
Values and preferences and patient engagement
when addressing all 19 recommendations
The values invoked in developing these 19 recommendations reflect
the combined views of all panelists, including the 2 patient
representatives. In all 19 recommendations, there was near unanimous
agreement regarding the importance of prevention, detection, and
treatment of CNS morbidity. The panelists rated the importance of
outcomes on a scale of 1 to 9, where ratings of 7 to 9 reflect outcomes
of critical importance to the decision at hand. As a guiding principle, all
members of the panel placed a higher value on maintaining cognitive
function than on being alive with minimal cognitive function
(significantly less than baseline functioning).
Organization, panel composition, planning,
and coordination
The work of this panel was coordinated with that of 4 other
guideline panels (addressing other aspects of SCD) by ASH and
the Mayo Evidence-Based Practice Research Center (funded by
ASH under a paid agreement). Project oversight was provided by a
coordination panel, which reported to the ASH Guideline Oversight
Subcommittee. ASH vetted individuals and appointed them to the
guideline panel. The Mayo Center vetted and retained researchers
to conduct systematic reviews of evidence and coordinate the
guideline development process including the use of the GRADE
Figure 1. High incidence of cerebrovascular accidents
in children and adults with SCD prior to the onset of
primary stroke prevention with transcranial Doppler
(TCD) and regular blood transfusion or hydroxyurea.
Data from the 3647 children and adults with SCD followed
prospectively from 1978 to 1988 in the Cooperative Study
for Sickle Cell Disease cohort. The incidence rates of
cerebrovascular accidents (CVA) were used to determine
CVA-free survival curves. The estimated age at first CVA was
significantly different for individuals with HbSS (SS) and
HbSC (SC; P , .001). Chances of having a first CVA by
20 years of age, 30 years of age, and 45 years of age were
estimated at 11%, 15%, and 24%, respectively, for HbSS
patients and 2%, 4%, and 10%, respectively, for those with
HbSC.1 Reprinted from Ohene-Frempong et al with
permission.1
Figure 2. Prevalence of SCIs in unselected children and adults
with HbSS or HbSb0 thalassemia. Silent cerebral infarcts (SCI)
were detected with MRI of the brain in children and adults with
HbSS or HbSb0 thalassemia and no history of focal neurological
deficits or strokes. Each point represents distinct cross-sectional
studies in children and adults with HbSS or HbSb0 thalassemia.4
Reprinted from Kassim et al with permission.4
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approach.30 The membership of the panels and the Mayo Center
team is described in supplemental File 1.
In addition to systematically synthesizing evidence, the Mayo Center
supported the guideline development process, including determin-
ing methods, preparing meeting materials, and facilitating panel
discussions. The panel’s work was done using web-based tools
(www.gradepro.org), as well as face-to-face and online meetings.
Guideline funding and management of conflicts
of interest
Development of these guidelines was wholly funded by ASH, a
nonprofit medical specialty society that represents hematologists.
ASH staff supported panel appointments and coordinated meet-
ings but had no role in choosing the guideline questions or
determining the recommendations.
Members of the guideline panel received travel reimbursement for
attendance at in-person meetings, and the patient representatives
received honorariums of $100 per day for in-person meetings and $25
per conference call. The panelists received no other payments.
Through the Mayo Clinic Evidence-Based Practice Research Program,
some researchers who contributed to the systematic evidence reviews
received salary or grant support. Other researchers participated to fulfill
requirements of an academic degree or program.
Conflicts of interest of all participants were managed through
disclosure, panel composition, and recusal, according to recom-
mendations of the Institute of Medicine33 and the Guidelines
International Network.14 Participants disclosed all financial and
nonfinancial interests relevant to the guideline topic. ASH staff and
the ASH Guideline Oversight Subcommittee reviewed the disclo-
sures and composed the guideline panel to include a diversity of
expertise and perspectives and avoid a majority of the panel having the
same or similar conflicts. Greatest attention was given to direct
financial conflicts with for-profit companies that could be directly
affected by the guidelines. A majority of the panel, including the joint
chairs, had no such conflicts. None of the Mayo-affiliated researchers
who contributed to the systematic evidence reviews or who supported
the guideline development process had any such conflicts.
Recusal was also used to manage conflicts of interest.14,34-36
During deliberations about recommendations, any panel member
with a current, direct financial interest in a commercial entity
that marketed any product that could be affected by a specific
recommendation participated in discussions about the evidence and
clinical context but was recused from making judgments or voting
about individual domains (eg, magnitude of desirable consequences)
and the direction and strength of the recommendation. The
EtD framework for each recommendation describes which
individuals were recused from making judgments about each
recommendation.
In 2019, after the guideline panel had agreed on recommendations,
it was discovered that 1 panelist had a direct financial conflict of
interest with an affected company (meals in 2017) that had not
been previously reported. The panelist had been recused for a
similar disclosure during the guideline meeting held to form
recommendations. Members of the Guideline Oversight Sub-
committee reviewed this late disclosure and determined no
additional action was required.
Supplemental File 2 provides the complete disclosure-of-interest
forms of all panel members. Individuals disclosed: direct financial
interests for 2 years prior to appointment in part A of the forms,
indirect financial interests in part B, and interests that were not
mainly financial in part C. Part D describes new interests disclosed
by individuals after appointment. Part E summarizes ASH decisions
about which interests were judged to be conflicts and how they
were managed, including through recusal.
Supplemental File 3 provides the complete disclosure-of-interest
forms of researchers who contributed to these guidelines.
Formulating specific clinical questions and
determining outcomes of interest
The panel met in-person and via conference calls to generate
possible questions to address. The panel then used an iterative
process to prioritize the questions described in Table 1. Questions
were formulated using the standard format of population, in-
tervention, comparison, and outcomes (PICO).
Following the approach described in detail elsewhere,37 the panel also
selected outcomes of interest for each question a priori. In brief, the
panel first discussed all possible outcomes before rating their relative
importance for decision-making following the GRADE approach.37
The panel acknowledged considerable variation in the clinical impact
Table 1. The 10 questions included by the Cerebrovascular Disease
Panel based on importance in preventing or decreasing
neurological morbidity in children and adults with SCD
PICO questions on preventing or decreasing neurological morbidity in
SCD
1 Should transfusion (vs no transfusion or hydroxyurea therapy) be used for children
aged 2-16 y with HbSS or HbSb0 thalassemia and abnormal nonimaging TCD
measurements?
2 Between 2 and 16 y of age, should children with HbS/Lepore disease, HbSE
disease, HbS/O Arab disease, or HbS/D disease phenotypes or other
compound heterozygous SCD phenotypes other than HbSC have TCD
screening at the same frequency and interval as children with HbSS or HbSb0
thalassemia?
3 Should annual screening with TCD be used for children between 2 and 16 y of age
with HbSS or HbSb0 thalassemia phenotypes from low-middle–income settings?
4 Should simple blood transfusion vs exchange transfusion be used for children and
adults with SCD and suspected acute symptomatic stroke, including TIA?
5 Should RBC transfusion targeted to keep HbS levels below 30% (vs no treatment),
RBC transfusion targeted to keep HbS levels above 30% and Hb above 9 g/dL,
or hydroxyurea at MTD therapy be used for children with SCD with a history of
stroke?
6 Should cerebral revascularization surgery (including EDAS, EDAMS, pial
synangiosis, or direct anastomosis) plus transfusion therapy vs regular blood
transfusion therapy alone be used for patients with SCD and moyamoya
syndrome?
7 Should IV thrombolysis with tPA vs no treatment with tPA be used for adults with
SCD presenting with acute ischemic stroke and no hemorrhage on CT scan
within 4.5 h of onset of symptoms?
8 Should clinicians perform or refer for screening for developmental delay and
cognitive impairment vs no screening in children and adults with SCD?
9 Should cognitive rehabilitation therapy vs no rehabilitation be used for children and
adults with SCD and cognitive impairment?
10 Should screening with MRI for SCIs vs no screening be used for children and
adults with HbSS or HbSb0 thalassemia?
EDAMS, encephalo-duro-arterio-myo-synangiosis; EDAS, encephalo-duro-arterio-synangiosis;
Hb, hemoglobin; MTD, maximum tolerated dose; PICO, population, intervention, comparison, and
outcomes; RBC, red blood cell; SCI, silent cerebral infarct; TIA, transient ischemic attack.
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of patient outcomes; they considered outcomes critical for clinical
decision-making across questions (Table 2).
Evidence review and development
of recommendations
Researchers at the Mayo Clinic Evidence-Based Practice Center
conducted new systematic reviews or updated existing systematic
reviews to answer the main 10 PICO questions. When existing
reviews were used, judgments of the original authors about risk of
bias were either randomly checked for accuracy and accepted or
conducted de novo if they were not available or not reproducible. In
addition to conducting systematic reviews of intervention effects,
the researchers sought evidence related to baseline risks, values,
preferences, and costs and summarized these findings within the
EtD frameworks.16,31 Subsequently, the certainty in the body of
evidence (also known as quality of the evidence or confidence in the
estimated effects) was assessed for each effect estimate of the
outcomes of interest following the GRADE approach based on
the following domains: risk of bias, precision, consistency and
magnitude of the estimates of effects, directness of the evidence,
risk of publication bias, presence of large effects, dose-response
relationship, and an assessment of the effect of residual, opposing
confounding factors. The certainty was categorized into 4 levels
ranging from very low to high.17-19
For each guideline question, the Mayo Center prepared a GRADE
EtD framework, using the GRADEpro Guideline Development
Tool (www.gradepro.org).16,21,22,31 The EtD table summarized the
results of systematic reviews of the literature that were updated or
performed for this guideline. The EtD table addressed effects of
interventions, resource utilization (cost-effectiveness), values and
preferences (relative importance of outcomes), equity, acceptability,
and feasibility. The guideline panel reviewed draft EtD tables before,
during, or after the guideline panel meeting, made suggestions for
corrections, and identified missing evidence. To ensure that recent
studies were not missed, in addition to searches presented in
supplemental File 4, panel members were asked to suggest any
studies that might have been considered missed that fulfilled the
inclusion criteria for the individual questions.
During a 2-day in-person meeting followed by online communication
and conference calls, the panel developed clinical recommenda-
tions based on the evidence summarized in the EtD tables. For each
recommendation, the panel took a population perspective and
came to a consensus on the following: the certainty in the evidence,
the balance of benefits and harms of the compared management
options, and the assumptions about the values and preferences
associated with the decision. The guideline panel also explicitly
considered the extent of resource use associated with alterna-
tive management options. The panel agreed on the recommen-
dations (including direction and strength), remarks, and
qualifications by consensus or, in rare instances, by voting (an
80% majority was required for a strong recommendation), based
on the balance of all desirable and undesirable consequences.
The final guidelines, including recommendations, were reviewed
and approved by all members of the panel. The approach is
described in detail in a previous article describing the methods of
development.30
Interpretation of strong and
conditional recommendations
The recommendations are labeled as either “strong” or “condi-
tional” according to the GRADE approach. The words “the
guideline panel recommends” are used for strong recommenda-
tions, and “the guideline panel suggests” for conditional recom-
mendations. Table 3 provides GRADE’s interpretation of strong and
conditional recommendations by patients, clinicians, health care
policy makers, and researchers.
Interpretation of good practice statements
As described by the GRADE Guidance Group, good practice
statements endorse interventions or practices that the guideline
panel agreed have unequivocal net benefit yet may not be widely
recognized or used.22 Good practice statements in these
guidelines are not based on a systematic review of available
evidence. Nevertheless, they may be interpreted as strong
recommendations.
Document review
Draft recommendations were reviewed by all members of the panel,
revised, and then made available online on 24 September 2018,
or for external review by stakeholders including allied organizations,
other medical professionals, patients, and the public. Eighteen
individuals or organizations submitted comments. The document
was revised to address pertinent comments, but no changes were
made to recommendations. The guidelines were reviewed by the
ASH Guideline Oversight Subcommittee on 10 October 2019. On
21 October 2019, the ASH Committee on Quality confirmed that
the defined guideline development process was followed, and, on
25 October 2019, the officers of the ASH Executive Committee
Table 2. Outcomes prioritized by the ASH Guideline Panel on
Cerebrovascular Disease
PICO question(s) Critical outcomes for decision-making
1, 2, and 3 Stroke
4 Stroke recurrence
5 TIA
Stroke recurrence
Acute chest syndrome
Acute pain episode
Total adverse events
6 Stroke recurrence
SCI
Mortality
Postoperative complications including postoperative subdural
hygroma; seizure; cerebral edema; subarachnoid and
interventricular hemorrhage
7 Improved functional outcome after stroke
Mortality
Intracranial and other major hemorrhage
8 Intelligence quotient/cognitive impairment, intelligence
developmental delay, school performance
9 Cognitive impairment and school and work performance
10 SCI
Developmental delay, school and work performance, and
cognitive impairment
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approved submission of the guidelines for publication under the
imprimatur of ASH. The guidelines were then subjected to peer
review by Blood Advances.
How to use these guidelines
ASH guidelines are primarily intended to help clinicians make decisions
about diagnostic and treatment alternatives. Other purposes are to
inform policy, education, and advocacy and to state future research
needs. They may also be used by patients. These guidelines are not
intended to serve or be construed as a standard of care. Clinicians must
make decisions based on the clinical presentation of each individual
patient, ideally through a shared process that considers the patient’s
values and preferences with respect to the anticipated outcomes of the
chosen option. Decisions may be constrained by the realities of a
specific clinical setting and local resources, including but not limited to
institutional policies, time limitations, or availability of treatments. These
guidelinesmay not include all appropriatemethods of care for the clinical
scenarios described. As science advances and new evidence becomes
available, recommendations may become outdated. Following these
guidelines cannot guarantee successful outcomes. ASH does not
warrant or guarantee any products described in these guidelines.
Statements about the underlying values and preferences as well as
qualifying remarks accompanying each recommendation are its
integral parts and serve to facilitate more accurate interpretation.
They should never be omitted when quoting or translating
recommendations from these guidelines. Implementation of the
guidelines will be facilitated by the related interactive forthcoming
decision aids. The use of these guidelines is also facilitated by the
links to the EtD frameworks and interactive summary of findings
tables in each section.
Recommendations
Screening with TCD and primary stroke prevention
Should transfusion (vs no transfusion or hydroxyurea therapy)
be used for children aged 2 to 16 years with HbSS or HbSb0
thalassemia and abnormal TCD measurements?
Between 2 and 16 years of age, should children with HbS/Lepore
disease, HbSE disease, HbS/O Arab disease, or HbS/D disease
phenotypes or other compound heterozygous SCD pheno-
types other than HbSC have TCD screening at the same
frequency and interval as children with HbSS or HbSb0
thalassemia?
Should annual screening with TCD be used for children between 2
and 16 years of age with HbSS or HbSb0 thalassemia phenotypes
from low-middle–income settings?
Recommendation 1.1
For children with HbSS or HbSb0 thalassemia (ages 2-16
years), the ASH guideline panel recommends annual TCD
screening (strong recommendation based on moderate cer-
tainty in the evidence about effects ÅÅÅ◯).
Recommendation 1.2
For children who have compound heterozygous SCD other
than HbSC and have evidence of hemolysis in the same range
as those with HbSS, the ASH guideline panel suggests TCD
screening (conditional recommendation based on very low
certainty in the evidence about effects Å◯◯◯).
Recommendation 2.1
For children with HbSS or HbSb0 thalassemia (ages 2-16 years)
who have abnormal TCD velocities and live in a high-income
setting (where regular blood transfusion therapy, typically
every 3-4 weeks, is feasible to maintain the maximum HbS
level ,30% and maintain the hemoglobin level .9.0 g/dL),
the ASH guideline panel recommends regular blood trans-
fusion for at least a year (vs no transfusion) with the goal of
keeping maximum HbS levels below 30% and maintaining
hemoglobin levels .9.0 g/dL to reduce the risk of stroke
(strong recommendation based on moderate certainty in the
evidence about effects ÅÅÅ◯).
Table 3. Interpretation of strong and conditional recommendations
Implications for Strong recommendation Conditional recommendation
Patients Most individuals in this situation would want the recommended
course of action, and only a small proportion would not
The majority of individuals in this situation would want the
suggested course of action, but many would not; decision aids
may be useful in helping patients to make decisions consistent
with their individual risks, values, and preferences
Clinicians Most individuals should follow the recommended course of action;
formal decision aids are not likely to be needed to help individual
patients make decisions consistent with their values and
preferences
Different choices will be appropriate for individual patients;
clinicians must help each patient arrive at a management
decision consistent with the patient’s values and preferences;
decision aids may be useful in helping individuals make decisions
consistent with their individual risks, values, and preferences
Policy makers The recommendation can be adopted as policy in most situations;
adherence to this recommendation according to the guideline
could be used as a quality criterion or performance indicator
Policymaking will require substantial debate and involvement of
various stakeholders; performance measures should assess
whether decision-making is appropriate
Researchers The recommendation is supported by credible research or other
convincing judgments that make additional research unlikely to
alter the recommendation; on occasion, a strong
recommendation is based on low or very low certainty in the
evidence; in such instances, further research may provide
important information that alters the recommendations
The recommendation is likely to be strengthened (for future
updates or adaptation) by additional research; an evaluation of
the conditions and criteria (and the related judgments, research
evidence, and additional considerations) that determined the
conditional (rather than strong) recommendation will help
identify possible research gaps
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Recommendation 2.2
For children who have compound heterozygous SCD other
than HbSC, who have evidence of hemolysis in the same range
as those with HbSS, an abnormal TCD velocity, and who live in
a high-income setting (where regular blood transfusion therapy
is feasible), the ASH guideline panel suggests regular blood
transfusion for at least a year (vs no transfusion) with the goal of
keeping maximum HbS levels below 30% to reduce the risk of
stroke and maintaining the minimum hemoglobin .9.0 g/dL
(conditional recommendation based on very low certainty in the
evidence about effects Å◯◯◯).
Recommendation 2.3
For children with SCD (ages 2-16 years) and abnormal TCD
results who have been receiving transfusion therapy for at least 1
year, and are interested in stopping transfusion, according to the
clinical trial risk stratification with an MRI and MRA of the brain (see
Technical remarks in supplemental File 5), the ASH guideline panel
suggests that hydroxyurea treatment at themaximum tolerated dose
can be considered to substitute for regular blood transfusions.
Remarks:
1. For children with abnormal TCD results and without
MRA-defined vasculopathy or silent cerebral infarcts who have
received at least 1 year of transfusions, based on the entry
criteria of the TCD With Transfusions Changing to Hydroxy-
urea (TWiTCH) Trial, hydroxyurea therapy treatment, at
the maximum tolerated dose, should be considered as a
replacement for regular blood transfusion therapy.
2. For children with abnormal TCD results, MRA-defined
vasculopathy, or silent cerebral infarcts, based on the exclusion
criteria of the TWiTCH Trial, continue regular blood transfu-
sions indefinitely.
(Conditional recommendation based on low certainty in the
evidence about effects ÅÅ◯◯).
Remarks for recommendations 1 and 2:
1. Recommendations 1 and 2 are applicable to countries
or settings in which regular blood transfusion is feasible and
acceptable.
2. The suggested threshold for treatment is 2 nonimaging
TCD measurements .200 cm/s, a time-averaged mean of the
maximum velocity (TAMMV) of $200 cm/s or a single
measurement .220 cm/s in the distal internal carotid artery
or proximal middle cerebral artery.
3. If the imaging TCD technique is used for assessment,
then 2 measurements greater than a time-averaged mean
maximum (TAMX) of $185 cm/s or a single measurement
.205 cm/s is required in the distal internal carotid artery or
proximal middle cerebral artery.
4. Predictive values of the TCD measurements in the other
intracranial arteries have not been rigorously addressed and
should not be used to stratify children into high- and low-risk
groups for future strokes.
5. For recommendations 1.2 and 2.2, the threshold for
hemolysis requiring regular TCD surveillance should be
determined based on the individual patient characteristics.
Consideration should be given to hemoglobin level, reticulocyte
count, and degree of hemolysis in relationship to HbSS.
6. For recommendations 1.2 and 2.2, we could not define a
laboratory threshold to determine who should undergo TCD.
Also, no evidence was available demonstrating that children
with HbSC should undergo TCD screening for primary stroke
prevention.
Recommendation 3
For children (ages 2-16 years) with HbSS or HbSb0 thalas-
semia or compound heterozygous SCD, who have abnormal
TCD screening, and live in low-middle-income settings (where
regular blood transfusion therapy and chelation therapy are
not available or affordable), the ASH guideline panel sug-
gests hydroxyurea therapy with at least 20 mg/kg per day
at a fixed dose or the maximum tolerated dose (conditional
recommendation based on low certainty in the evidence about
effects ÅÅ◯◯).
Remark:
Recommendation 3 is applicable to low-middle–income
settings and locations in which regular blood transfusion is
not feasible. For children with abnormal TCD velocities in this
setting, the optimal hydroxyurea dose and the appropriate
infrastructure support required to safely administer hydroxyurea
and to follow the patients for expected toxicities have not been
determined.
Specific background. Applying the results of the Optimizing
Primary Stroke Prevention in Sickle Cell Anemia Trial (STOP) has
contributed to one of the greatest advances in management of SCD.
TCD screening coupled with regular blood transfusion therapy for
those with an abnormal TAMMV TCDmeasurement is associated with
a 92% reduction in stroke incidence compared with observation
alone.38 The threshold for regular blood transfusion therapy is 2
nonimaging TCD measurements $200 cm/s or a single TAMMV
measurement.220 cm/s in the proximal portion of themiddle cerebral
artery or the distal portion of the internal carotid artery (Figure 1 in
supplemental File 5). Two TCD measurements are required for values
$200 cm/s and ,220 cm/s because of the ultrasonographer’s large
coefficient of variation up to 12% of TCD measurement in the same
child with HbSS measured only 3 hours apart.39 Furthermore, a large
intrasubject standard deviation of the TCD measurement occurs;
in 812 children with HbSS and HbSb0 thalassemia and TCD
measurements with at least 2 examinations in ,6 months with no
intervention, the standard deviation of the TAMMV was 14.9 cm/s.40
The peak systolic TCD velocity has not been applied as a predictor
of initial stroke in a randomized controlled trial. These peak velocities
are generated automatically from the TCD machine and cannot be
used to stratify children for primary stroke prevention. Unfortunately,
the TCD peak systolic velocity is sometimes confused with TAMMV,
and as a result, patients can be inadvertently transfused.
STOP 2 demonstrated that, for STOP participants who received
transfusions for 30 months or longer and whose TCD measurements
became normal, continued regular blood transfusion was required to
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prevent strokes or reversion to abnormal TCDmeasurements.41 Thus,
children with abnormal TCD measurements are presumed to have an
indefinite risk of strokes. In summary, the results for STOP and STOP
2 demonstrated a clear benefit of regular blood transfusion compared
with no transfusions (observation) (Figure 3). STOP 2 excluded
children with severe stenotic lesions on cerebral MRA.
The optimal interval for reassessment of children with conditional
TCD measurements (170-199 cm/s) has not been determined, but
reassessment is commonly done within 6 months, and often sooner.
The HbSS and HbSb0 thalassemia phenotypes were both eligible
for STOP and STOP 2, in part because of clinical challenges of
distinguishing HbSS from HbSb0 thalassemia using clinical
laboratory values42 and the fact that both diagnoses have been
included in primary stroke prevention stroke trials.38,41
If the imaging TCD technique rather than the nonimaging technique
is used, then 2 measurements greater than the TAMX ($185 cm/s)
or a single TAMXmeasurement.205 cm/s is required.25 To ensure
that proper velocity thresholds are used for clinical decision-
making, clinicians should determine which type of TCD (imaging
or nonimaging) is used at their center. Regardless of whether
the imaging or nonimaging TCD is used, the threshold for
treatment should not be based on peak systolic velocity (Figure 1 in
supplemental File 5).
Children evaluated for abnormal TCD measurement should not
have a recent blood transfusion because of the known association
between TCD velocities and transfusions.43 Typically, the TCD
measurement should be done at least 3 months after the last
transfusion and when the child is at their baseline state of health.
Treatment with regular blood transfusion commonly requires iron
chelation therapy to attenuate excessive stores of iron that
accumulate with blood transfusion. If a child who had abnormal
TCD screening measurement meeting criteria for transitioning to
maximum tolerated dose of hydroxyurea, after 1 year of regular
blood transfusion therapy, a discussion with the family should
include whether hydroxyurea is preferable to regular blood trans-
fusion therapy.44 Prior to consideration of transitioning from regular
blood transfusion therapy to maximum tolerated dose of hydroxy-
urea, MRI of the brain should be completed to exclude silent
cerebral ischemic lesions (see Table 1 PICO #10), and intracranial
MRA should be completed to determine the presence and extent of
cerebral vasculopathy, per the TWiTCH protocol.44
Given that the incidence rate of strokes was extremely low in the
blood transfusion arm of the STOP Trial,,1 stroke per 100 patient-
years,38 no formal assessment of stroke risk factors in the treatment
arm of STOP can be used to determine the subgroup of children
likely to have a stroke while receiving regular blood transfusion
therapy.38 In the STOP 2 Trial for those randomly allocated to
receive regular blood transfusion therapy, 21.6% (19 of 88) had
persistent abnormal TCD measurements, with a mean follow-up of
2.4 years with no stroke occurrence.45
A small population of children with SCD (,3%) who are compound
heterozygotes for HbS and do not have HbSC are at high risk of
stroke. The utility of TCD screening in children with compound
heterozygous SCD is not well defined. Given the relationship
between TCD values and hemoglobin levels in children with
HbSS,43 and the association between low hemoglobin levels and
strokes,1 the evidence suggests that TCD screening and treatment
will likely prevent strokes for children with compound heterozygous
SCD and have evidence of hemolysis in a range similar to that of
children with HbSS. The decision as to which children with
compound heterozygous SCD should receive TCD screening
and subsequent treatment should be made on an individual
basis. In children with compound heterozygous SCD, we cannot
identify a single marker of hemolysis or a threshold for markers of
hemolysis that should be screened. For children with HbSC, the risk
of abnormal TCD measurements and stroke is less than for those
with HbSS.46
Hemoglobin levels in children with HbSb1 thalassemia vary. The
range is from hemoglobin levels of 7 g/dL to values within the
normal range. The low hemoglobin levels are accompanied by
magnitudes of hemolysis markers similar to those seen in
children with HbSS. Consequently, we cannot state with high
certainty which children with HbSb1 thalassemia should receive
TCD screening.
In a low-middle–income setting, without any primary stroke
prevention strategy, ;11% of the children with HbSS or HbSb0
thalassemia will have a stroke before their 18th birthday.1 For
ASH’s guidelines to have a significant impact on primary stroke
prevention in children with HbSS or HbSb0 thalassemia, a
meaningful strategy must be aligned with public health policy
that can be implemented in children with HbSS living in low-
middle–income settings.
In an optimal implemented primary stroke program in high-income
settings, ,1% of the children who receive TCD screening coupled
with regular blood transfusion therapy for abnormal TCD
Figure 3. STOP trial results. Results of the STOP trial and STOP 2.38,41 TCD
screening coupled with regular blood transfusion therapy for those with an abnormal
TCD measurement (TAMMV . 200 cm/s) was associated with a 92% reduction in
stroke incidence compared with observation alone.38 The threshold for treatment is
2 nonimaging TCD measurements .200 cm/s, TAMMV of $200 cm/s, or a single
measurement .220 cm/s.38 Reprinted from Adams et al with permission.38
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measurements will have strokes.2 For children with an abnormal
TCD measurement, the risk of ischemic strokes is exceptionally
high: 10.7 strokes per 100 patient-years.38
In untreated adults with atrial fibrillation, the stroke incidence rate is
;4.4 events per 100 patient-years.47 The higher incidence of
ischemic stroke risk for children with abnormal TCD measurements,
when compared with adults with untreated atrial fibrillation, clearly
demonstrates the potential public health impact of preventing
strokes in children with HbSS or HbSb0 thalassemia in both low-
middle– and high-income settings.
The clinical experience of the panel, coupled with evidence from the
literature, indicates that regular blood transfusion therapy is not a
feasible option for the majority of children living in Africa or other
low-middle–income settings. When presented with the benefits of
blood transfusion for primary and secondary stroke prevention in
Nigeria, caregivers uniformly elected for children not to receive
regular blood transfusion.48 The reasons for not accepting regular
blood transfusions include the annual cost of transfusions, the cost
of iron chelation therapy, and the risk of a blood-borne infection or of
life-threatening transfusion reactions.
Summary of the evidence. The systematic review identified
3 randomized controlled trials at low risk of bias addressing the
first question (transfusion of children with HbSS or HbSb0
thalassemia and abnormal TCDs), no comparative studies
addressing the second question (transfusion of other geno-
types), and 1 nonrandomized study for question 3 (hydroxyurea
in children with abnormal TCD measurements in low-middle–
income settings).
The evidence summary and EtD framework can be found online at:
https://guidelines.gradepro.org/profile/a34d09131753ee2f22fcaec
5b2510f11, https://guidelines.gradepro.org/profile/b9ab114a172c
fa3dab8c60ae5d7ba0b0, and https://guidelines.gradepro.org/profile/
fe67f197d72505e0299c9557312b83b9.
Rationale and expected benefits. The primary premise for our
recommendations is that there is clear evidence from 3 National
Heart, Lung, and Blood Institute (NHLBI)–funded controlled trials
describing38,41,44 the benefit of identifying children between 2
and 16 years of age with HbSS or HbSb0 thalassemia and
abnormal TCD measurements (TAMMV .200 cm/s). The initial
treatments for abnormal TCD measurements were regular blood
transfusion, with therapy transitioned to maximally tolerated
hydroxyurea therapy after 1 year of transfusion, for patients with
MRA-defined vasculopathy. Secondary benefits of regular blood
transfusion therapy include a decrease in the severity of the
disease. No dissent was observed in the panel regarding the
importance of identifying the risk of an initial stroke and providing
caregivers with the option to select the best treatment of primary
stroke prevention for the child.
The controlled clinical trials primarily addressed the question of
whether children with abnormal TCD measurements (TAMMV,
.200 cm/s) should receive regular blood transfusion, hydroxyurea
therapy, or no therapy to reduce the high risk of stroke. One
randomized controlled trial, STOP,38 included children with HbSS
and HbSb0 thalassemia screened for abnormal TCD measure-
ments (TAMMV, .200 cm/s) and then randomly allocated to be
treated with regular blood transfusion therapy or observation for
primary stroke prevention.
For participants in STOP, one follow-up trial was completed,
STOP 2,41 which included those randomly allocated in STOP who
received regular blood transfusions for 30 months or longer and
whose TCD measurements became ,200 cm/s during that time.
The former eligible STOP participants were randomly assigned to
continue regular blood transfusion therapy or observation. The
results demonstrated a clear benefit of ongoing regular blood
transfusion therapy despite TCD measurements decreasing to
,200 cm/s.41 Our recommendations are based on the strength of
the evidence of these trials, which demonstrate the benefit of
transfusion for primary stroke prevention.
TWiTCH is the only randomized controlled trial providing evidence
for the safety of transitioning children with abnormal TCD velocities
to the maximum tolerated dose of hydroxyurea. Children in this trial
had no evidence of MRA-defined vasculopathy, had been receiving
regular blood transfusion therapy for at least 1 year, and were
escalated to the maximum tolerated dose of hydroxyurea.44 We do
not have sufficient evidence to determine whether the group of
children with abnormal TCD measurements and MRA-defined
vasculopathy would remain stroke-free if transitioned from regular
blood transfusion therapy to hydroxyurea because they were
excluded from the TWiTCH trial.
In STOP, the group of children with the highest rate of stroke were
those in the observation arm who had both abnormal TCD
measurements and silent cerebral infarct at baseline. In this group,
51% (15 of 29) had a stroke, compared with 22% (9 of 40) in the
observation group with abnormal TCD measurements and no silent
cerebral infarct.49 Early evidence from small observational studies
suggests that hydroxyurea alone may not attenuate cerebral infarct
recurrence in adults with silent cerebral infarct.26,27
A consortium of French investigators demonstrated that children
with HbSS or HbSb0 thalassemia treated with regular blood
transfusion for abnormal TCD velocities had lower TCD velocities 1
year after matched sibling donor hematopoietic stem cell trans-
plantation (HSCT) compared with children treated with hydroxyurea
therapy.50 These data suggest that HSCT is a reasonable option for
children with SCD and abnormal TCD when performed in a clinical
trial setting.50 However, this work should be considered preliminary
because the long-term benefit vs the risk of using HSCT for primary
stroke prevention has not been systematically studied, including the
late effects of myeloablative and nonmyeloablative therapy in
children and adults with SCD. Formal clinical trials are required to
determine the optimal HSCT strategy for primary stroke prevention
in HbSS or HbSb0 thalassemia.
The primary premise for our PICO #3 recommendation (see
Table 1) is based on the observation that ;95% of children with
HbSS live in low-middle–income settings,7 coupled with the
urgency to prevent strokes in children, in the absence of a
randomized controlled trial conducted in low-middle–income
settings. Among children with HbSS and abnormal or conditional
TCD measurement living in low-middle–income and high-income
settings, data from observational studies consistently demonstrate
that hydroxyurea lowers TCD measurements.51-60
The largest observational study that focused exclusively on primary
stroke prevention in a low-middle–income country was conducted
in Ibadan, Nigeria, and demonstrated the benefit of hydroxyurea
for primary stroke prevention.60 Lagunju et al showed that
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children with conditional (n 5 60) and abnormal (n 5 44) TCD
velocities taking hydroxyurea that started at 10 mg/kg,
escalated to the maximum tolerated dose (20-35 mg/kg), and
followed for a mean of 3.6 years had a mean drop in TAMMV
from 198 cm/s to 169.3 cm/s. One stroke occurred in a child
whose TAMMV remained abnormal despite adherence to
hydroxyurea, and the calculated incidence rate for overt stroke
was 0.27 per 100 person-years.60 There was also a child with
TIA whose TAMMV remained abnormal after 15 months; this
child had hydroxyurea discontinued because of mucositis, but
had achieved a dose of 20 mg/kg per day. Leukopenia and
neutropenia were not seen at this hydroxyurea dose.60 Another
study, conducted in Kano, Nigeria, was a feasibility trial for
primary stroke prevention for children with abnormal TCD
measurements. In this study, 27 children with abnormal TCD
measurements were given a fixed dose of hydroxyurea 20 mg/kg
per day.39 Among the children with abnormal TCD measure-
ments, hydroxyurea resulted in a mean TAMMV decrease of
18 cm/s and no strokes; with a total of 74 person-years, median
follow up of approximately 2 years, and expected number of
strokes of approimately 8 (10.7 per 100 patient-years).
To obtain additional evidence that hydroxyurea decreases TCD
measurements, the panel reviewed 10 studies in children with
HbSS or HbSb0 thalassemia who had TCD measurements at
baseline and several months after starting hydroxyurea therapy
(Figure 4). The decrease in TCD measurements can occur as early
as 3 months after starting hydroxyurea therapy with a sustained
impact of hydroxyurea therapy on decreasing TCD measurements
for at least 36 months. In a pooled analysis of 10 studies, the
average drop in TCD measurement after starting hydroxyurea,
21 cm/s, was a clinically relevant decline (Figure 4).
Further data on the safety of hydroxyurea therapy in Africa was clearly
demonstrated in a large prospective controlled trial recently reported
from 4 sub-Saharan African centers (Luanda, Angola; Kinshasa,
Democratic Republic of the Congo; Kilifi, Kenya; and Mbale,
Uganda). The rate of clinical adverse events during the pretreatment
phase (2 months) was compared with the treatment phase (mean, 29
months). During the treatment phase, there was a significant
decrease in the incidence rates for death, malaria, and acute vaso-
occlusive events; data on stroke were not presented separately.61
Taken together, these studies demonstrate that hydroxyurea
therapy39,60,61 is safe for children in Africa, effective in decreasing
TCD velocities, and reduces the incidence rate of mortality and
morbidity. These studies provide a compelling rationale for the use of
hydroxyurea for primary stroke prevention in children with abnormal
TCD measurements in low-middle–income settings61 as additional
trials with CNS complications as end points are conducted.39
The hydroxyurea dose used in Nigeria for primary stroke prevention
ranges from a fixed moderate dose of 20 mg/kg,39 which typically
does not require monthly full blood count monitoring, as performed
in clinical trials, to maximum tolerated dose (typically;25-35 mg/kg
per day) that requires monitoring every 2 to 3 months with complete
blood counts.60,61 A randomized clinical trial for primary stroke prevention
in Nigeria for children with HbSS and abnormal TCD is comparing
moderate-dose hydroxyurea (20mg/kg per day) to low-dose hydroxyurea
(10 mg/kg per day) with results anticipated in 2021 (NCT02560935).
The optimal health care visit schedule for monitoring hydroxyurea
therapy for primary stroke prevention in low-middle–income settings
is not known. The primary purpose for this visit is for the health care
provider to reinforce adherence to the therapy, adjust the dose of
hydroxyurea due to the increasing weight of the growing child, and
evaluate for toxicity, particularly myelosuppression. After stabiliza-
tion on the maximum tolerated dose of hydroxyurea, monitoring
blood counts every 8 weeks appears to be safe.61 Insufficient data
were available to make a recommendation on the clinical utility of
TCD screening in adolescents .16 years of age and adults with
HbSS and HbSb0 thalassemia.
Summary of harms and burden. The potential harms associ-
ated with regular blood transfusion therapy have been quantified
in controlled clinical trials for primary and secondary prevention
strokes in children with HbSS or HbSb0 thalassemia. These
adverse events include, but are not limited to, the following, in
decreasing order of prevalence: excessive iron stores62,63 that
may eventually require chelation therapy,64 red blood cell
alloimmunization,25,65 and adverse blood transfusion reactions.64
The family makes a significant time commitment when they agree to
regular blood transfusion therapy. Typically, blood transfusions
occur monthly and often require 2 visits (the first for cross-
matching of the red blood cell units and the second for the actual
blood transfusion). We did not find a study describing the full
range of challenges of regular blood transfusion therapy for
families, but the panel, including the 2 patient representatives,
believed strongly that family preferences and the inconvenience
and financial resources associated with regular blood transfusion
therapy should be considered when making a decision to include
this therapy.
In low-middle–income settings without public health care insurance
systems to pay for hydroxyurea, the costs of hydroxyurea and
complete blood cell counts assessments for myelosuppression may
be prohibitive for most families. We did not identify a study
reviewing the challenges of regular hydroxyurea therapy for families
living in low-middle–income settings. The consensus among the
panel was that some form of local or federal government subsidy
for primary stroke prevention is required to have a sustainable
program to treat the maximum number of children with abnormal
TCD measurements living in low-middle–income settings. For
instance, in Nigeria alone, 150 000 children are born with HbSS
each year.66 Conceivably, 10% of each cohort of children born in
the same year (15 000 children before 16 years of age) will
have an abnormal TCD and will require primary stroke prevention.
All panel members strongly believed that regardless of location
in a high-income country or a low-middle–income country, the
health care systems’ first obligation for following the panel
guidelines was to prevent strokes in children with HbSS and
HbSb0 thalassemia.
EtD criteria and implementation consideration. We com-
bined HbSS and HbSb0 thalassemia phenotypes because of the
clinical challenges of distinguishing HbSS from HbSb0 thalassemia
based on clinical laboratory values42 and the fact that both diagnoses
were eligible for primary stroke prevention trials.38,41
Patient representatives on the panel disclosed that regular blood
transfusion therapy is less acceptable to some individuals with
SCD and their caregivers. However, based on the extensive
experience of the panel, blood transfusion therapy is acceptable
to many caregivers and children with HbSS or HbSb0 thalassemia
phenotypes and abnormal TCD measurements. Transfusion is
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more feasible in high-income settings than in low-middle–income
settings. Despite the lack of adequate cost-effectiveness studies,
preventing strokes in children will always be less expensive than the
long-term direct and indirect consequences of stroke and stroke-
related death and disability, regardless of whether stroke preven-
tion treatment is performed with transfusion and chelation therapy
or hydroxyurea. The decision criteria are likely the same for children with
other SCD compound heterozygotes at increased risk for stroke.
Hydroxyurea therapy requires at least the same health care system
resources in a low-middle–income setting as those in high-income
settings, including laboratory surveillance at the same interval as in a
high-income setting (initially every 2 weeks and eventually every 2 or
3 months). Most likely, hydroxyurea therapy is more acceptable than
transfusion for primary stroke prevention for patients and families.
Health equity for stroke prevention in children living with SCD in
low-middle– and high-income settings can potentially reduce the
existing health disparities in childhood stroke prevalence between
children with and without SCD.
The objective of regular blood transfusion is to maintain hemoglobin
levels above 9 g/dL, but below 13 g/dL and pretransfusion HbS
below 30%. Some patients will be difficult to transfuse effectively to
keep the HbS ,30% on a consistent basis.67,68 If the HbS cannot
be kept consistently ,30% with either simple transfusion,
manual exchange transfusion, or automated exchange trans-
fusion, higher HbS-level thresholds of ;35% to 40% are
acceptable provided that the patient is consistently transfused
at 3- to 4-week intervals.
After 1 year of regular blood transfusion therapy, a gradual transition
from transfusion to hydroxyurea can be considered. This involves a
period of both hydroxyurea therapy and transfusion therapy, with
eventual discontinuation of transfusion therapy. The transition may
occur provided that the patient does not have intracranial MRA-
defined vasculopathy as per TWiTCH.44 Prior to consideration of
transitioning from regular blood transfusion therapy to maximum-
tolerated-dose hydroxyurea, MRI of the brain should be undertaken
to exclude silent cerebral ischemic lesions (see Table 1 PICO #10)
and intracranial MRA to determine the presence and extent of
cerebral vasculopathy. Children with cerebral vasculopathy were
excluded from TWiTCH; therefore, transition from blood transfusion
therapy to hydroxyurea is not recommended for these children. A
discussion with the family should include whether hydroxyurea at
the maximum tolerated dose is preferable to regular blood transfusion
with chelation therapy to attenuate excessive stores of iron.44
Research needs. The panel identified the following additional
areas in need of research.
1. Best practices and implementation strategies for primary stroke
prevention after using TCD as a screening tool should be
determined. Over a 6-year study period among 4775 children
with HbSS or HbSb0 thalassemia from 6 US states, 22% to
44% of children received TCD screening.69
2. Alternative options for primary stroke prevention other than initial
regular blood transfusion therapy for a year for some, then
followed by maximum tolerated dose of hydroxyurea therapy,
should be identified for children living in high-income settings.
3. Imaging strategies to identify the subgroup of children with an
abnormal TCD measurement who are most likely to have a
stroke should be improved. The current number needed to treat
is 7 (ie, 7 children with abnormal TCD measurements must
receive at least monthly blood transfusion therapy for at least a
year to prevent 1 stroke). Strategies to personalize the risk of
stroke for children with abnormal TCD measurements would be
preferred to the current standard of red blood cell transfusion
therapy for at least a year for children living in high-income
settings for at least a year.
4. The optimal hydroxyurea dose (20 mg/kg per day vs 10 mg/kg
per day vs the maximum tolerated dose of hydroxyurea) for primary
stroke prevention in children with abnormal TCD measurement
living in low-middle–income settings should be determined.
5. Use of a liquid formulation of hydroxyurea that is stable at
room temperature when stored at home and can be provided
to children ,5 years of age unable to swallow a capsule is
needed.
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Figure 4. Pooled analysis of the 10 studies documenting TCD measurement before and after hydroxyurea therapy in children with HbSS or HbSb0
thalassemia. This meta-analysis demonstrates the average drop in TCD measurement after starting hydroxyurea therapy of 21 cm/s (95% confidence interval [CI], 14.8-29.0).
The plot also suggests that the decrease in TCD measurements can be seen as early as 3 months after the start of hydroxyurea therapy with a sustained impact of hydroxyurea
therapy on decreasing TCD measurements for at least 36 months. The analysis is updated from a previous one by DeBaun and Kirkham,58 plus additional references.51-57,59,60,165
♦ represents the pooled estimate from a random-effect model, the edges of the diamonds represent the 95% CI; n represents individual studies. MTD, maximum tolerated dose.
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6. The best strategies to partner with local, state, and federal
health care authorities in low-middle–income settings to provide
hydroxyurea therapy for primary stroke prevention programs
should be determined.
7. Training and quality assurance of TCD practitioners to increase
the pool of qualified TCD practitioners, particularly in low-middle–
income settings, are needed.
Should simple blood transfusion vs exchange transfusion be used
for children and adults with SCD and suspected acute symptom-
atic stroke, including TIA?
Recommendation 4.1
For children or adults with SCD and acute neurological deficits,
including TIA, the ASH guideline panel recommends prompt
blood transfusion. The transfusion should be given immediately
upon recognition of symptoms without delay beyond 2 hours of
acute neurological symptom presentation. The type of trans-
fusion (simple, modified exchange, or apheresis) is dependent
on individual patient factors and local transfusion resources
(strong recommendation based on high certainty in the evi-
dence about effects ÅÅÅÅ).
Recommendation 4.2
For children or adults with SCD and acute neurological deficits
including TIA, the ASH guideline panel suggests exchange
transfusion vs simple transfusion. When exchange transfusion
is not available within 2 hours of presentation for medical
care and hemoglobin is #8.5 g/dL, simple transfusion can
be performed to avoid delays in treatment while a manual
exchange transfusion or an automated apheresis is planned
(conditional recommendation based on low certainty in the
evidence about effects ÅÅ◯◯).
Remarks:
1. Optimal timing of therapy is to have prompt (within 2
hours of presentation to medical care) transfusion in children
and adults with SCD presenting within 72 hours of symptom
onset of a suspected acute stroke, new neurologic deficit, or
TIA.
2. For children and adults with a new neurologic deficit or
TIA presenting to medical care .72 hours after onset and
without recent worsening, an assessment for anemia and
percentage of sickle hemoglobin with consideration of trans-
fusion on a case-by-case basis is suggested.
3. For individuals with hemoglobin levels .8.5 g/dL
presenting with focal neurological deficits or TIA, exchange
transfusion therapy to decrease the possibility of hyperviscosity
syndrome is suggested.
Specific background. Ischemic strokes in children and adults
with SCD are one of the most important and common medical
emergencies, particularly in regions where primary stroke pre-
vention is not standard care. When a patient with SCD presents
with an ischemic stroke or a TIA, timely response is required to
minimize further ischemic injury. Optimal timing of intervention with
blood transfusion therapy and brain-imaging modality has not been
rigorously studied. However, in SCD, the principles of management
of acute ischemic strokes and TIAs, coupled with observational
studies, provide evidence for best practices
Summary of the evidence. The systematic review identified 1
nonrandomized study that compared simple transfusion to
exchange transfusion.
The evidence summary and EtD framework can be found online at:
https://guidelines.gradepro.org/profile/bc68e8f1c23c576c468a5dca
4557cb68.
Rationale and expected benefits. In the absence of random-
ized clinical trials, no set of guidelines is likely to address the full
spectrum of brain imaging and interventions for decreasing
ischemic injury to the brain that represent evidence-based best
practices; however, the principles of cerebral hemodynamics
specific to SCD, coupled with multidisciplinary experiences of the
panel, provide practical approaches.
Children and adults with SCD presenting with focal neurological
deficits suggestive of stroke or TIA require rapid evaluation and
close consultative interaction between hematologists, neurologists,
and acute-care providers because the diagnosis of an acute
ischemic stroke can be challenging (Figure 2 in supplemental File
5). If a hematologist or a health care practitioner skilled in managing
exchange transfusion and acute stroke management in HbSS is not
immediately available, appropriate care should be initiated with low-
flow oxygen, IV fluids, complete blood count, and crossmatching;
the patient should be sent to a facility with the required expertise to
manage acute ischemic strokes and SCD. The differential diagnosis
is broad (Figure 2 in supplemental File 5), and management of acute
ischemic brain injury in children and adults with SCD continues
to evolve.
The final diagnosis of ischemic stroke or TIA is based on a complete
neurological history. An MRI of the brain may facilitate a diagnosis of
acute cerebral ischemia, but cannot replace a history and
examination The absence of abnormality seen on the diffusion-
weighted image on MRI of the brain does not definitively exclude
the diagnosis of an ischemic stroke.70 If a patient with SCD
presents with an acute-onset focal neurological deficit and the
health care provider believes that the patient has had an ischemic
stroke or TIA, intervention should be the same to minimize the
potential risk of ongoing ischemic brain injury.
Only one retrospective observational study in children with SCD
provides the empiric data for the recommendation of an exchange
transfusion (apheresis or manual) vs only simple transfusion for
acute management of ischemic strokes. In this retrospective cohort
study, children with HbSS or HbSb0 thalassemia and acute
ischemic stroke patients receiving simple transfusion for an acute
ischemic stroke had a higher rate of recurrent strokes than children
who received exchange transfusion (relative risk [RR], 5.0; 95%
confidence interval [CI], 1.3-18.6).71
The preponderance of evidence supporting the recommendation
for transfusion for acute ischemic stroke is from detailed cerebral
hemodynamic studies in children and adults with SCD.72,73 In SCD,
cerebral blood flow is increased compared with that in the general
population,74,75 and flow is inversely related to arterial oxygen
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content (flow increases as oxygen content decreases).75 Oxygen
delivery to the brain is the product of cardiac output and arterial
oxygen content, which is primarily determined by the product of
hemoglobin concentration and hemoglobin oxygen saturation. Both
children and adults with SCD have altered cerebral hemodynamics
resulting from the unique properties of sickled red blood cells, acute
and chronic anemia,1,74,76 and cerebral vasculopathy.77 Concomitant
complications of SCD such as acute chest syndrome can also
reduce oxygen delivery, and cerebral metabolic demand is increased
in conditions such as fever and seizures.76 Both overt ischemic
strokes and silent cerebral infarcts in SCD typically occur in areas
between cerebral large vessel vascular territories, also called the
cerebral border zone, with the lowest cerebral blood flow.78
For children and adults presenting with a focal neurological deficit
suggestive of an ischemic event, including a TIA, increasing the
hemoglobin level with a red blood cell transfusion is the best option
to achieve the goal of improving oxygen delivery to the brain. If the
hemoglobin level is less than ;8.5 g/dL, the panel recommends
increasing the hemoglobin to ;10.0 g/dL with a simple transfusion
within 2 hours after presentation to medical care. After the
hemoglobin has reached ;10.0 g/dL with simple transfusion or if
the baseline hemoglobin level is greater than ;8.5 g/dL, the panel
recommends an automated-exchange red blood cell transfusion
(apheresis).79 This procedure will require a timely dialogue, initiated
soon after presentation to the medical facility, between the
transfusion service, the hematologist, and intensivist to ensure
a multidisciplinary approach to management. If red blood cell
exchange with apheresis is not a viable option, the patient should
be stabilized and either transferred promptly to a facility that can
perform apheresis or manual red blood cell exchange should be
undertaken on site.80,81 The optimal strategy for manual red blood
cell exchange for acute ischemic events has not been de-
termined, but several options exist for reasonable starting points
for providers that cannot offer apheresis in low-middle– and high-
income settings.80,81
Unique attributes of SCD that are important for acute ischemic injury
(suspected stroke or TIA) include the observation that as hemoglobin
increases to a point, there is a corresponding increase in oxygen
delivery.82,83 However, beyond this point any increase in hemoglobin
concentration decreases the arterial oxygen delivery. For patients
with HbSS or HbSb0 thalassemia receiving simple transfusions, the
point of diminishing benefit of arterial oxygen delivery is estimated to
be between 10 and 11 g/dL82,83 (Figure 5).80
Evidence suggests that oxygen delivery to the brain in SCD is
dependent not only on the total hemoglobin concentration, but also
on the percentage of HbS.84 Thus, the goal of the red blood cell
exchange with apheresis is to lower the percentage of HbS while
preventing a rise in hemoglobin level above a threshold that may
cause viscosity-related complications. Thresholds for postapheresis
HbS percentage and hemoglobin level are typically set at 15% to
20% and 10 g/dL, respectively. The HbS level of 15% to 20%
allows a threshold of ,30% HbS to persist for ;4 weeks. When
the HbS level is ,20%, the total hemoglobin level can generally be
.10 g/dL, up to ;12 to 13 g/dL, without concerns for viscosity-
related complications, and the optimal recommended range of
hemoglobin level postapheresis is 10 to 12 g/dL. When the
hemoglobin level is ,5.0 g/dL, a simple transfusion to increase the
total hemoglobin to ;10.0 g/dL may be required. Generally, red
blood cell exchange with apheresis is not recommended for
patients with SCD and hemoglobin levels ,5.0 g/dL, in part
because of concerns of lowering the hemoglobin level during
priming of the apheresis machine. We identified an algorithm for
acute management of suspected ischemic stroke or TIA in children
and adults (Figures 6 and 7, respectively).
Based on the concept that “time is brain” and the urgency of rapid
stroke care in the general adult population, we suggest similar
urgency for treatment in SCD as soon as possible after presentation
to medical care.85 Although we suggest a threshold time interval for
consideration of exchange transfusion of 72 hours, this is based
only on expert opinion. Few data are available to inform the question
of the time interval for potential clinical benefit from red blood cell
transfusion therapy after stroke onset in children and adults with SCD.
Supportive care in the acute poststroke period should reflect AHA
guidelines, which suggest avoiding hyperglycemia, hypoglycemia,
hyperpyrexia (treating temperatures of .38°C with antipyretics),
and hypotension.86 As in adult stroke, early evidence in childhood
stroke suggests that hypertension in the acute period after stroke is
associated with worse outcomes.87 There is not enough evidence
in children with SCD to make formal recommendations regarding
treatment of blood pressure, but many centers allow blood pressure
above prestroke baseline and treat blood pressures that are
consistently above the 95th percentile for age and height.88 Given
the observation that blood pressures in individuals with SCD are
generally lower than in the general population,89 knowing the patients
baseline blood pressure (prestroke) may facilitate blood pressure
management at the time of stroke.
Summary of harm and burden. The main complications of
prompt treatment with simple blood or an exchange transfusion are
those associated with blood transfusion and with the requirement
for central line placement for red blood cell exchange with apher-
esis. Complications of regular blood transfusion include blood
Figure 5. Relationship between hemoglobin level and oxygen delivery in
individuals with SCD. The maximal hemoglobin (Hbmax) to deliver oxygen transport
in sickle cell patients is 10 to 11 g/dL because SCD alters red cell viscosity and
decreases oxygen transport. However, when the HbS level is low (;20%), this impairment
of oxygen transport is improved, and a higher hemoglobin level (such as 13 g/dL) may be
beneficial. Red cell apheresis can rapidly lower the HbS to levels that maximize oxygen
delivery, in contrast to the risks of simple transfusion resulting in increased viscosity
and decreased oxygen delivery.82,83 Professional illustration by Patrick Lane, ScEYEnce
Studios. Adapted from Swerdlow with permission.80
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transfusion reactions,64 blood-borne infection, alloimmunization,25,65
and excessive iron stores,62,63,90 which typically requires iron chelation
therapy.64 Complications of central line placement include inadvertent
vascular injury, local infection at the site of the central line placement,
and systemic infection and catheter-related venous thrombosis. Overall,
timely treatment with blood transfusion therapy for acute ischemic injury
of the brain was deemed to outweigh the risk of treatment.
EtD criteria and implementation considerations.
Prevention of recurrent stroke or extension of stroke will decrease
the magnitude of stroke-related disability and mortality in children and
adults with SCD, improving health equity. In terms of feasibility and
acceptability, exchange transfusion often requires admission to an
intensive care unit (ICU) and central line placement; however, the
procedure can also be done in a non-ICU setting and with peripheral
venous access if peripheral veins are adequate. Management of
central line thrombosis or infection is challenging. Exchange trans-
fusion by automated apheresis is not always immediately available. If
apheresis is not available within 2 hours, strong consideration should
be given to manual exchange or transfer to a center where automated
apheresis can be performed.
Research needs. The panel identified the following additional
areas in need of research.
1. Evidence to define the optimal interval between onset of
ischemic stroke or TIA and transfusion is needed. The time
point at which there is no longer a benefit or at which risk
outweighs benefit is unknown.
2. Development of additional therapeutic strategies or alternatives
to blood transfusion is needed for better prevention of
progressive brain injury after an initial acute ischemic stroke.
3. A more precise understanding of the mechanisms of cerebral
hemodynamics in children and adults with SCD is needed to
develop targeted therapies and to improve risk stratification for
initial and subsequent cerebral infarct and cerebral hemorrhage.
Should red blood cell transfusion targeted to keep HbS levels
below 30% (vs no treatment) or hydroxyurea therapy be used for
children with SCD with a history of stroke?
Recommendation 5
For children with HbSS or HbSb0 thalassemia and a history of
prior ischemic stroke, the ASH guideline panel recommends
blood transfusion goals for secondary stroke prevention of in-
creasing the hemoglobin greater than 9 g/dL at all times and
maintaining the HbS level at ,30% of total hemoglobin until
the time of the next transfusion (strong recommendation based
on low certainty in the evidence about effects ÅÅ◯◯).
Remarks:
1. The ASH guideline panel acknowledges that for children
who cannot be transfused or refuse transfusion, hydroxyurea
therapy is an inferior alternative to regular blood transfusion for
secondary stroke prevention, but superior to no therapy at all
for secondary stroke prevention.
2. Adolescents who had a stroke as a child should continue
transfusion into adulthood for secondary stroke prevention.
3. Adults who suffer their first stroke as an adult should
receive the recommended evaluation for stroke-modifiable risk
factors according to AHA guidelines. Secondary stroke
prevention should include regular blood transfusion and other
AHA-recommended measures.
Specific background. Strokes in children and adults with
HbSS or HbSb0 thalassemia are one of the most common and
devastating complications of the disease that produce lifelong
sequelae, including but not limited to cognitive morbidity, increased
risk of future cerebral infarcts, and earlier death.
Summary of the evidence. The systematic review identified
12 studies, one of which was randomized and 4 of which were
Figure 6. Algorithm of management of acute suspected ischemic
stroke in children with SCD. The goal is prompt transfusion beginning
within 2 hours of presentation to medical care to achieve hemoglobin of
10 g/dL and an HbS level of 15% to 20%. *See text for PICO question 4 or
established inclusion and exclusion criteria. Professional illustration by Patrick
Lane, ScEYEnce Studios.
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nonrandomized comparative studies. The evidence summary and
EtD framework can be found online at: https://guidelines.grade-
pro.org/profile/c9d01e0189434d904716b2360f56c103.
Rationale and expected benefits. Children and adults with
HbSS or HbSb0 thalassemia and strokes (overt) have ongoing
risk for infarct recurrence even when receiving regular blood
transfusion therapy. In 2 large multicenter retrospective cohort
studies, children with HbSS or HbSb0 thalassemia receiving
regular blood transfusion therapy had ongoing risk of future
symptomatic ischemic strokes. In the first large multicenter
retrospective cohort study, 60 children with strokes (ischemic)
receiving regular blood transfusion therapy were followed for a
total of 191 patient-years. The incidence of stroke recurrence
was 4.2 per 100 patient-years. There was a statistically
significant reduction in stroke incidence compared with histor-
ical controls who had strokes and did not receive regular blood
transfusion therapy.91 In a second large retrospective multicenter
study, 137 children with strokes were followed for a total of 1382
patient-years (mean, 10.1 years; minimum, 5 years; maximum,
24 years) with an incidence rate of 2.2 events per 100 patient-
years.76 HbS levels at the time of stroke recurrence were available
for only 19% of patients, and most of the HbS values were ,30%.
In a prospective multicenter single-arm trial of 40 children with
strokes followed for a median of 5.4 years (total, 222 patient-years),
the incidence of strokes was 3.1 events per 100 patient-years.92
All participants received regular blood transfusion with a mean
pretransfusion HbS level of 29%, indicating that the goal of keeping
maximum HbS concentration ,30% was met. Furthermore, in this
cohort, there was progressive vasculopathy on MRA imaging, with
recurrent overt or silent cerebral infarct (RR, 12.7; 95% CI, 2.65-
60.5; P5 .01). Taken together, these 3 studies provide evidence that
regular blood transfusion therapy is partially effective for secondary
prevention of strokes in children and adults with HbSS or HbSb0
thalassemia. However, recurrent stroke risk while patients are
receiving regular blood transfusion therapy remains significant.
Hydroxyurea therapy is inferior to regular blood transfusion for
secondary stroke prevention in children with HbSS or HbSb0
thalassemia. No data exist for the other SCD phenotypes. In a
single-center prospective feasibility study, 35 children on regular
transfusion with a previous history of stroke were transitioned
to hydroxyurea at the maximal tolerated dose and had serial
phlebotomy to reduce transfusion iron overload. The stroke
recurrence rate was 5.7 events per 100 patient-years. Phlebotomy
significantly lowered iron burden and normalized hepatic iron.93
Figure 7. Algorithm of management of acute suspected ischemic stroke in adults with SCD. The goal is prompt transfusion beginning within 2 hours of presentation
to medical care to achieve hemoglobin of 10 g/dL and an HbS level of 15% to 20%. *See PICO questions 4 and 7 or established inclusion and exclusion criteria. Professional
illustration by Patrick Lane, ScEYEnce Studios.
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However, the analysis was not adjusted for the period of time with
the highest rate of recurrent stroke, that is, the first 2 years.11,76,94
Based on these results, a phase 3 noninferiority randomized
controlled trial, Stroke With Transfusions Changing to Hydroxyurea
(SWiTCH), was conducted.95 In this trial, hydroxyurea at the
maximal tolerated dose combined with phlebotomy was found to
be inferior to continuing transfusion together with the ongoing
requirement of iron chelation therapy because of excessive iron
stores. The rate of secondary stroke was 5.6 events per 100
patient-years in the hydroxyurea arm compared with 0 events per
100 patient-years for children who continued with transfusion
(the standard-care arm).95 The NHLBI leadership closed
SWiTCH after interim analysis revealed equivalent liver iron
content, indicating futility for the composite primary end point of
allowing an increase in stroke, but requiring superiority for
removing iron.
Where transfusion is not available, hydroxyurea therapy is better
for secondary stroke prevention than no treatment at all. In a
prospective nonrandomized study in Nigeria,96 13 children received
hydroxyurea therapy, whereas 18 caregivers declined hydroxyurea
therapy for their children. Maximum dose of hydroxyurea ranged
from 20 to 25 mg/kg per day. The secondary stroke incidence of 7
events per 100 person-years in the hydroxyurea group was
significantly lower than the 28 per 100 person-years in the
nontreatment group (P 5 .001; odds ratio [OR], 3.80; 95% CI,
1.55-9.31).96
Overall, studies indicate that regular blood transfusion and
hydroxyurea therapy are palliative for secondary prevention of
strokes in children and adults with HbSS or HbSb0 thalassemia,
with blood transfusion being superior to hydroxyurea therapy and
both therapies being superior to no therapy.
For children and adults with strokes and severe cerebral
vasculopathy (moyamoya syndrome), alternative treatments
such as revascularization surgery may be considered as adjunct
therapy to regular blood transfusion therapy for secondary stroke
prevention. HSCT is considered a curative50,97,98 and definitive
option for secondary stroke prevention for children with matched
related donors97 or haploidentical bone marrow transplantation
with posttransplantation cyclophosphamide.98,99 Recent studies
have revealed that new cerebral infarcts are detected after
central adjudication of neuroimaging and neurology examination
are performed as part of the HSCT protocol.100,101 Individuals
and their families should be informed of the potential long-term
benefits and long-term risks of secondary stroke prevention
therapies.
Current and future therapeutic options for secondary stroke
prevention should be considered in the context of a multicenter
clinical trial setting with peer review, a data safety monitoring
board to assess safety and futility, a study design that includes
long-term follow-up of at least 5 years, and central adjudication
of all neurological events. Without such approaches, there will
continue to be less-than-optimal data to inform families about
best strategies for secondary stroke prevention.
Summary of harms and burden. The potential harms associ-
ated with regular blood transfusion therapy have been quantified in
controlled clinical trials for primary and secondary prevention of
strokes in children with HbSS or HbSb0 thalassemia.
These adverse events include, but are not limited to, the following,
in decreasing order of prevalence: excessive iron stores62,63,90
that may eventually require chelation therapy,64 red blood cell
alloimmunization,25,65 and adverse blood transfusion reactions.64
The family makes a significant time commitment when they agree to
regular blood transfusion therapy. Typically, blood transfusion
occurs monthly and often requires 2 visits (the first for cross-
matching of the red blood cell units and the second for the actual
blood transfusion). We did not find a study describing the full range
of challenges of regular blood transfusion therapy for families, but
the panel, including the 2 patient representatives, believed strongly
that family preferences and the inconvenience and financial
resources associated with regular blood transfusion therapy should
be considered.
EtD criteria and implementation considerations. Despite the
absence of a randomized controlled clinical trial comparing regular
blood transfusion to maintain HbS level ,30% and minimum
hemoglobin .9.0 g/dL, a strong recommendation was made
despite low-quality evidence based on the large difference in
outcomes (stroke rate per 100 patient-years) that favored trans-
fusion to maintain the HbS level at ,30% when compared with no
treatment of secondary stroke prevention. Additionally, the commit-
tee relied heavily on the studies describing the cerebral hemody-
namics specific to SCD, the unique rheological studies of SCD,
coupled with multidisciplinary experiences of the panel. The panel
placed a high value on the uncertain, but potentially quality-of-life
preserving, benefit of the intervention. Moreover, the burden and
harms of transfusion were not felt to be prohibitive given the
panelists’ and patients’ values focusing on reducing the risk of
stroke over possible burdens and harms. Regular blood trans-
fusion programs are resource-intensive. Patients’ and parents’
acceptance are variable. Caring for children in situations in which
caregivers have strong beliefs against blood transfusion therapy
may require that a court order be obtained in the best interest of
the minor to provide the maximum benefit of decreasing future
stroke recurrences.
Research needs. The panel identified the following additional
areas in need of research.
1. Optimal therapeutic strategies for secondary stroke prevention
in children and adults (blood transfusion therapy vs blood
transfusion therapy plus revascularization surgery vs HSCT)
with long-term follow-up in children and adults with SCD
are needed.
2. Optimal therapeutic strategies or secondary stroke prevention
in low-middle–income settings where blood transfusion therapy
is not available are needed.
3. Optimal transfusion targets and methods for secondary stroke
prevention are needed.
4. Risk stratification to identify the group of children and adults with
strokes likely to have infarct recurrence should be carried out.
5. Optimal treatment and stroke recurrence rate for children and
adults other than those with HbSS or HbSb0 thalassemia
should be determined.
Should cerebral revascularization surgery (including EDAS,
EDAMS, pial synangiosis, or direct anastomosis) plus regu-
lar blood transfusion therapy vs regular blood transfusion
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therapy alone be used for patients with SCD and moyamoya
syndrome?
Recommendation 6
For adults and children with SCD, moyamoya syndrome, and a
history of stroke or TIA, the ASH guideline panel suggests
evaluation for candidacy for revascularization surgery in addi-
tion to continuing regular blood transfusions (conditional rec-
ommendation based on very low certainty in the evidence
about effects Å◯◯◯).
Remarks:
1. Without evidence, but with compelling extensive expe-
rience, the panel endorses a multidisciplinary team evaluation
including a hematologist, neurologist, neuroradiologist, and
neurovascular surgeon for evaluation of the pros and cons of
surgical evaluation and optimization of patients’ health before,
during, and after surgery. The evaluation neither supports nor
negates performing 1 of the 5 different revascularization
procedures, but rather provides the background information
for shared decision-making to consider surgery based on the
available evidence for benefits and risks. However, if neuro-
surgery is considered, then a multidisciplinary evaluation is
strongly preferred.
2. For individuals who undergo revascularization surgery,
standardized care protocols and long-term outcome tracking
(for a minimum of 5 years) through a local, national, or
international prospective registry are encouraged.
3. Which of the 5 revascularization approaches, plus
ongoing blood transfusion therapy, is more effective in
secondary stroke prevention than regular blood transfusions
alone is unclear. The quality of the studies does not allow for
a pooled analysis nor an evidence-based recommendation-
specific procedure with clear benefit, hence the reason for
prospective standardized protocols and long-term outcome
tracking.
Specific background. Progression of cerebral infarcts and
cerebral vasculopathy is common despite regular blood transfusion
therapy for secondary stroke prevention. Some patients progress to
a moyamoya vasculopathy with high risk of TIA, ischemic and
hemorrhagic stroke,102 and cognitive decline.103 Outcome studies of
children and adults with SCD who have moyamoya and have had a
stroke have been generally limited to small or single-center series,
with little follow-up beyond 5 years.104-111 No rigorous pro-
spective controlled trial has been done to compare the benefits
and risks of revascularization surgery plus regular blood trans-
fusion therapy to regular blood transfusion therapy alone for
secondary stroke prevention in children and adults with SCD and
moyamoya syndrome.
Several studies have compared the incidence of strokes before and
after revascularization surgery; however, such studies are in-
trinsically limited. The highest incidence rate for cerebral infarct
recurrence occurs within 2 years of initial stroke, with or without
preventive treatment.11,76,94 Table 1 in supplemental File 5 has
the most recent summary of the revascularization procedures
performed in SCD and the list of adverse outcomes that occur
primarily in the first month after revascularization procedures.
No pooled analysis of the studies could be completed
because of the heterogeneity of the 5 different neurosurgery
procedures (pial synangiosis, encephalo-duro-arterio-myo-
synangiosis [EDAMS], encephalo-duro-arterio-synangiosis
[EDAS], encephalo-myo-arterio-synangiosis, multiple burr holes),
and the lack of uniform neurological assessment (surveillance of
MRI of the brain and neurology assessment for infarct recurrence)
during the follow-up period.
Future studies designed to assess the added utility of surgical
revascularization in SCD-related moyamoya syndrome for
secondary stroke prevention should include surveillance MRIs
of the brain to identify silent cerebral infarcts, formal neurolog-
ical assessment by a neurologist to identify subtle neurologic
deficits associated with overt strokes because these subtle
changes may alter the recommendation for future therapy, and
adjustment for the high-risk period of stroke recurrence. To
date, none of the published studies of cerebral revascularization
in SCD have included these strategies to improve the scientific
rigor of these studies, thus limiting the inferences of the
potential benefit.
Summary of the evidence. The systematic review identified 13
nonrandomized studies (Table 1). Five of the included studies were
comparative (surgical intervention plus transfusion vs regular blood
transfusion without surgery). The other 8 studies were noncompar-
ative. Most studies did not report the SCD phenotypes of the
participants, a major consideration for stroke recurrence.
The evidence summary and EtD framework can be found online at:
https://guidelines.gradepro.org/profile/5bf40c8e961a95877aefa0
af3d23dd09.
Rationale and expected benefits. Most studies addressing
the benefit and risk with cerebral revascularization surgery (pial
synangiosis, EDAMS, EDAS, encephalo-myo-arterio-synangiosis,
multiple burr holes) have been single-center observational studies
(Table 1 in supplemental File 5). Due to the small sample sizes, the
variation in revascularization procedures, and the incomplete
reporting of the outcomes, studies could not be grouped to
provide a composite assessment of the benefit of cerebral
revascularization surgery. The type of revascularization approach
that is most effective is unclear and depends on the individual
patient, clinical context, and availability of surgical expertise.
Further secondary stroke prevention studies in children and adults
with SCD are needed to explore the risk-to-benefit ratio for
surgery in addition to other therapies such as HSCT.
Summary of harms and burden. The potential harms asso-
ciated with cerebral revascularization procedures are consider-
able and include intraoperative and postoperative complications
associated with SCD and periprocedural ischemic and hemor-
rhagic stroke. Surgical risk may be higher in children and adults
with SCD than in the general population, so studies of cerebral
revascularization for moyamoya syndrome in other populations
may not be generalizable to patients with SCD. Given the small,
single-center studies, coupled with the limited follow-up time
(most ,5 years), particularly compared with the lifespan of
adults with SCD, the long-term benefits and risks of these
revascularization procedures in children and adults with strokes
and moyamoya syndrome have not been adequately assessed.
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We included studies only of individuals with strokes and
moyamoya syndrome. We did not have sufficient evidence to
evaluate surgery in children and adults with SCD and moyamoya
syndrome alone or moyamoya syndrome and silent cerebral
infarcts.
Hydroxyurea is a myelosuppressive agent and may impair wound
healing. Hydroxyurea, when given before or after revascularization
surgery, may prevent sprouting and growth of new cerebral blood
vessels, as well as impairing wound healing after revascularization
surgery.112,113
EtD criteria and implementation considerations. Data on
values and preferences, cost-effectiveness, acceptability, and
feasibility of revascularization procedures are lacking. Vari-
ability in surgical expertise can limit the broad implementation
of this recommendation. We also expect a wide range of how
much an individual may value the immediate risk of perioperative
and postoperative complications vs possible reduction of risk
of a long-term outcome such as stroke, cognitive decline, or
both.
Research needs. The panel identified the following additional
areas in need of research.
1. Rigorous studies that include longitudinal outcomes after
revascularization surgery for moyamoya syndrome in SCD are
needed.
2. Multicenter prospective studies or registries for individuals with
SCD and moyamoya syndrome should be conducted and
implemented as a first step to collect outcome data.
Should IV thrombolysis with tPA vs no treatment with tPA be
used for adults with SCD presenting with acute ischemic stroke
and no hemorrhage on CT scan within 4.5 hours of onset of
symptoms?
Recommendation 7
For adults with SCD presenting with symptoms of acute is-
chemic stroke and being considered for IV tPA (age $18
years, no hemorrhage on CT scan, within 4.5 hours of onset of
signs, symptoms, and without contraindications for throm-
bolysis), the ASH guideline panel suggests management us-
ing a shared decision-making approach that follows these
principles:
1. For all patients, the administration of tPA should not
delay prompt simple or exchange blood transfusion therapy.
2. Patients may be evaluated for IV tPA based on its
established inclusion and exclusion criteria detailed in stroke-
management algorithms.
3. The following factors suggest likely benefit from IV
tPA: older age, atrial fibrillation, diabetes, hypertension, and
hyperlipidemia. Management of younger patients without
these risk factors should emphasize early transfusion.
4. There are no validated risk stratification or reliable age
cutoff criteria to guide the choice of initial therapy.
5. IV tPA is not recommended for children with SCD (,18
years of age).
(Conditional recommendation based on very low certainty in
the evidence about effects Å◯◯◯).
Remarks:
1. For Recommendation 7, the ASH guideline panel
recognizes that prompt identification of an adult with SCD
presenting to the emergency department with focal neurolog-
ical deficit and balancing the timely treatment with IV tPA and
timely treatment with blood transfusion therapy is challenging
(Recommendations 4.1 and 4.2).
2. Evidence does not exist as to which treatment option
should be provided first (tPA or blood transfusion). Concep-
tually, prioritization of treatment should be informed by
underlying stroke etiology (SCD vs non-SCD), but this may
not be clear in the hyperacute setting.
3. Given the increased overall survival of adults with SCD
into middle and old age with the cumulative effect of traditional
cardiovascular risk factors leading to stroke, offering emergent
treatment with tPA to older adults with SCD presenting with
acute ischemic strokes within 4.5 hours of symptom onset is
advised. However, no absolute age cutoff could be defined.
4. In some cases, the treatment with tPA may occur before
the patient has been recognized as having SCD. In such
instances, blood transfusion should be considered as soon as
possible after SCD is identified.
5. A systematic review on endovascular thrombectomy
was not performed because we are unaware of any interven-
tional studies specific to SCD; although multiple large clinical
trials support thrombectomy for stroke in selected patients with
acute large vessel occlusion outside SCD.
6. Evidence supports endovascular thrombectomy for
stroke with acute large vessel occlusion in the general
population; however, we do not have evidence of the risks
and benefits in adults with SCD.
7. The utility of endovascular thrombectomy in adults with
SCD should be carefully evaluated due to the prevalence of
cerebral vasculopathy and moyamoya syndrome and the
absence of data describing the benefits and risks.
Specific background. To date, only one study has examined
the use of tPA in adults with SCD.114 Overall, the SCD population is
younger at the time of a first stroke and includes a higher proportion of
people with hemorrhagic stroke compared with all adults with strokes.
Summary of the evidence. The systematic review identified 3
nonrandomized studies, 1 of which was comparative. The other
2 were case reports. The evidence summary and EtD framework
can be found online at: https://guidelines.gradepro.org/profile/
c960529ed37314a2f4804dbd6a48ee31.
Rationale and expected benefits. For adults with SCD
presenting within 4.5 hours of the time when they were last seen
to be normal after ischemic stroke onset who meet established
eligibility criteria, IV tPA improves functional outcomes at 3 to 6
months poststroke.115 One study of tPA for hyperacute stroke
compared outcomes of adults with and without an SCD diagnosis
using administrative data from a large US health provider.114 There
was no difference in efficacy or safety outcomes between the 2
groups, but the study was limited by lack of confirmation of SCD
phenotype and probable inclusion of individuals with sickle cell trait.
Although recognizing that the expected benefit of IV tPA for
adults with SCD may differ from that in general medical practice
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because stroke etiologies differ, the ASH guideline panel
suggests that adults with SCD and acute ischemic stroke be
considered for IV tPA following established guidelines because
of the strong evidence for improved outcomes in the general
population. However, evidence for the benefit of tPA in adults
with SCD is scant, and the potential harm associated with tPA is
significant.
Summary of harms and burden. Major risks of tPA include
symptomatic intracerebral hemorrhage in 3% to 6% and life-
threatening systemic hemorrhage.116 Use of thrombolytics for acute
stroke may also delay prompt blood transfusion. tPA administration
in a young adult with SCD presenting with an ischemic stroke may
delay the administration of regular blood transfusion therapy, a
therapy with a clear benefit in this population. The timing of tPA and
acute blood transfusion therapy should be individually based.
EtD criteria and implementation considerations. The
acceptability and feasibility of the panel’s recommendation not to
delay transfusion are limited by prehospital emergency medical
systems that direct patients with suspected stroke to certified
stroke centers, where stroke teams are trained to reduce door-to-
needle times for treatment with IV tPA. Rapid implementation of
stroke protocols for IV tPA treatment may result in the missed
opportunity for prompt transfusion, particularly if adults are not
identified with SCD. Conversely, stroke protocols typically
suggest placement of 2 large-bore IV lines on arrival to medical
care, which could facilitate more rapid simple transfusion and
possibly exchange transfusion. Joint protocols including both IV
tPA and transfusion should be developed by stroke teams and
hematologists for rapid identification and management of patients
with SCD presenting with acute ischemic stroke. A proxy with
power of attorney is often beneficial for shared decision-making in
the emergency setting when an acute stroke occurs.
Research needs. The panel identified the following additional
areas in need of research.
1. Rigorous studies of the safety of tPA use in individuals
confirmed to have SCD and acute ischemic stroke are needed.
2. Systematic data collection in adults with SCD receiving IV tPA
that includes stroke risk factors, presumed stroke etiology after
workup, and outcomes should be carried out.
3. Implementation science studies designed to identify the optimal
clinical practice for administering both tPA and acute blood
transfusion therapy to adults with SCD presenting to the
emergency department with acute ischemic strokes are needed.
Should clinicians perform or refer for screening for developmental
delay and cognitive impairment vs no screening in children and
adults with SCD?
Recommendation 8.1
Given the high prevalence of developmental delay and cognitive
impairment, coupled with the guidelines set by the American
Academy of Pediatrics, the ASH guideline panel recommends
that clinicians supervising care of children with SCD conduct
surveillance using simplified signaling questions for the following:
1. Concerns about developmental delays in preschool-age
children
2. Concerns about neurodevelopmental disorders in school-
age children with SCD, such as academic or behavioral
problems or symptoms of inattention, hyperactivity, or impulsivity.
(Strong recommendation based on low certainty in the
evidence about effects ÅÅ◯◯).
Recommendation 8.2
For children with SCD who have abnormal surveillance results
suggesting increased risk for developmental delay or cognitive
impairments, the ASH guideline panel recommends screening
or referral for formal screening by a psychologist or a pedia-
trician able to perform screening with the available validated
tools (strong recommendation based on low certainty in the
evidence about effects ÅÅ◯◯).
Recommendation 8.3
Given the high prevalence of cognitive impairment in adults
with SCD, coupled with the guidelines set by the American
Academy of Neurology, the ASH guideline panel recommends
that clinicians supervising care of adults with SCD conduct
surveillance for cognitive impairment using simplified signaling
questions (strong recommendation based on low certainty in
the evidence about effects ÅÅ◯◯).
Recommendation 8.4
For adults with SCD who have abnormal surveillance results
suggesting cognitive impairment, the ASH guideline panel
recommends formal referral to a psychologist or a primary care
physician able to perform more in-depth cognitive evaluation
(strong recommendation based on low certainty in the evi-
dence about effects ÅÅ◯◯).
Remark:
For Recommendation 8, the ASH guideline panel provides
specific examples of signaling questions that can be used for
screening in Table 2 in supplemental File 5.
Specific background. Cognitive impairment is perhaps the
most insidious CNS morbidity of SCD. In children with SCD,
there is a clear gradient in full-scale intelligence quotient (FSIQ)
depending on the degree of neurological injury (normal MRI, silent
cerebral infarct, or stroke). In the most comprehensive meta-
analysis to date, children with HbSS with normal MRIs of the brain,
silent cerebral infarct, and strokes had mean FSIQs of 91, 84, and
73, respectively.6 Few comprehensive cognitive studies in adults
with SCD have been done that include assessment of FSIQ,
employment status, and assessment of cerebral infarct status.
Despite the high prevalence of cognitive impairment, the diagnosis
is difficult to discern and challenging to ascertain because of the
requirement of formal cognitive testing.
In several health care settings, the potential for reimbursement is
increasing; for example, the American Medical Association Current
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Procedural Panel has developed a new billing code (96127) for
behavioral health screening that can be used to screen for cognitive
impairment.117 Physicians, nonpsychologist staff, and practitioners
have also seen a dramatic increase in cognitive screenings
conducted, indicating that surveillance and screening are possible in
settings without ready access to specialists in psychological
assessment.118 Both the American Psychological Association and
the National Academy of Neuropsychology have acknowledged that in
many health care settings there is a need for medical doctors or
nonpsychologist staff or practitioners to provide wider access to
cognitive or behavioral health screenings, and these organizations have
provided clarification on the distinction between screening and a more
comprehensive psychological assessment requiring a specialist.119,120
The specific tests for cognitive screening in children and adults with
SCD, and the optimal strategies to screen and implement
rehabilitation for cognitive impairments, have not been established.
Consequently, recommendations are extrapolated from non-SCD
populations. Evidence-based practices for screening for cognitive
impairments and rehabilitative interventions for cognitive function,
specifically executive dysfunction, are well-established and en-
dorsed practices in professional societies, such as the American
Academy of Pediatrics, the American Academy of Neurology, and
the American Congress of Rehabilitation Medicine. The guideline
panel relied heavily on well-established evidence-based practices
from these 3 prominent professional societies to identify strategies
for screening and treatment of cognitive morbidities.121-123
Summary of the evidence. The systematic review did not
identify any studies that compared screening to no screening. The
review identified 48 studies that evaluated cognitive screening
without a comparison group and reported outcomes of IQ score,
the prevalence of cognitive impairment, developmental delay, or
school performance. The evidence summary and EtD framework
can be found online at: https://guidelines.gradepro.org/profile/
72b18bf3a46115c0989f3068aa701629.
Rationale and expected benefits. The use of formal screen-
ing tools improves the ability to detect developmental delays or
cognitive impairment compared with informal observational
methods.124,125 Furthermore, the combination of surveillance and
screening appears to work better for identifying children in need of
developmental services than either method in isolation.126 Many
screening tools can be used in primary care or community settings,
require less administration time than full assessments, and can be
administered by staff with less training, so that access is increased
and burden to patients is decreased. See Tables 2 and 3 in
supplemental File 5 for established initial screening tools and
ongoing surveillance questions, respectively.
In the general population and in children and adults with SCD,
identification of children and adults with developmental or cognitive
delays increases likelihood of access to remediation services. In the
United States and in most European countries, laws mandate
interventions for children with significant developmental delay and
conditions that impact learning in a public setting. If the child is ,3
years of age, a significant developmental delay results in referral to
early intervention therapy and the child and family undergo
assessment for an individualized family service plan.127 Services
are typically provided in the home or “natural environment” and
include occupational therapy, physical therapy, developmental
therapy, and speech therapy. These services are provided to enhance
the development of the child. If the child or young adults is between 3
and 21 years of age, and a significant impairment is identified, the
local public school district is tasked with working with the family to
develop an individualized education program. The program provides
services in the public school educational setting including supple-
mental aides if indicated, learning accommodations, and modifica-
tions.127 Both the individualized family service plan and individualized
education plans include measurable goals, assessments, and
meetings to review the children’s progress. If a child is not making
progress, the plans are typically modified to provide better support.
A recent systematic review of cognition across the lifespan of people
with SCD confirmed that the magnitude of deficits increases as the
injury to the brain increases. On average, performance declined from
groups without infarct to those with silent cerebral infarct to those
with overt stroke.6 In addition, medium to large differences in
cognition between children with SCD and their siblings or controls
existed. Fewer adult studies were included, but small to large
differences between the adults with SCD and controls were
documented, with the greatest difference in processing speed.6
Vascular cognitive impairment is of particular concern in adults with SCD
and requires ongoing efforts to identify cognitive symptoms and medical
risk factors.128 Detection of cognitive impairments is important for
identifying treatable causes, helping patients and families to understand
the cause of functional deficits, and discussing the prognosis to
plan for future needs.123 Outpatient services such as speech therapy,
occupational therapy, or rehabilitation psychology may be indicated
and available depending on the results of a full evaluation.129
In general, children and adults with SCD are a vulnerable
population. The overwhelming majority of patients in the Unites
States with this condition are African American130 and living at or
near poverty level131-133; associated social factors such as parental
education attainment and measures of socioeconomic status impact
cognitive performance.134-137 In addition, in children with HbSS or
HbSb0 thalassemia and disease-associated morbidity such as low
oxygen hemoglobin saturation levels, silent cerebral infarcts and overt
strokes are all associated with lower FSIQ scores.134,138
Summary of harms and burden. There are few downsides to
surveillance and screening for cognitive impairment, developmental
impairments, or both, as part of routine health care. Available
cognitive-screening methods improve detection yet lack sufficient
sensitivity to be used as a substitute for clinical judgment.120 For
cases in which the patient’s history, risk factors, and functional
complaints indicate a high risk for cognitive impairment, screening
may be skipped in favor of directly referring for a comprehensive
assessment. False-positive results from screening can also result in
distress and inconvenience for patients and their families.139,140 Such
distress likely already exists for patients and families who already have
concerns about developmental delays or cognitive impairment.
EtD criteria and implementation considerations. The
quality of evidence demonstrating benefits of cognitive and
developmental screening specifically in individuals with SCD is
low. However, such screening is noninvasive and can lead to timely
referral to address those with developmental delays and cognitive
impairment. The harm of not addressing such deficits in children
and adults is severe on a personal and societal level. Therefore, a
low certainty in benefit but high certainty of harm (particularly from
other populations) justified a strong recommendation.141 When
considering patient values and preferences, the panel members,
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including the 2 patient representatives, reported values with little
variation in favor of screening.
Critical resources are needed to screen children and adults for
developmental delay and cognitive impairment. Such resources
are likely more available in medical centers with comprehensive
care for individuals with SCD than in primary care settings.
Resources and tools for screenings have been designed for
primary care settings and are widely available; however, practi-
tioners need to prioritize screening followed by periodic surveillance
as part of routine health care. Patients may have to travel to obtain
appropriate cognitive and developmental screening, particularly in
managed-care settings.
Research needs. The panel identified the following additional
areas in need of research.
1. Better documentation of the prevalence and progression of
cognitive impairments in adults with SCD is needed.
2. Evaluation of screening and surveillance approaches for
cognitive and developmental concerns assessed within the
SCD population should be developed, rather than relying on
data from broader populations.
3. Research evaluating implementation practices that produce the
best access to screening, surveillance, and assessment for
developmental delays and cognitive impairments, or both, is needed.
4. Future research is required to determine which development
and cognitive-screening tools have the highest clinical utility in
low-middle– and high-income settings.
Should cognitive rehabilitation therapy vs no rehabilitation be used
for children and adults with SCD and cognitive deficit?
Recommendation 9.1
For children with SCD and abnormal screening for de-
velopmental or cognitive status, the ASH guideline panel rec-
ommends the following:
1. A developmental, cognitive, medical evaluation to di-
agnose any related disorders and to identify modifiable risk
factors for developmental delays or cognitive impairments;
2. Following the cognitive domain-specific evidence-based
guidelines for these conditions to provide appropriate interventions.
(Strong recommendation based on high certainty in the
evidence about effects ÅÅÅÅ).
Recommendation 9.2
For adults with SCD and abnormal screening for cognitive
status, the ASH guideline panel recommends the following:
1. A developmental, cognitive, and medical evaluation to
diagnose any related disorders and to identify modifiable risk
factors for cognitive impairments;
2. Following the cognitive domain-specific evidence-based
guidelines for these conditions to provide appropriate interventions.
(Strong recommendation based on high certainty in the
evidence about effects ÅÅÅÅ).
Specific background. As previously mentioned, cognitive
impairment is perhaps the most insidious CNS morbidity of SCD.
Evidence-based rehabilitative interventions for cognitive function,
specifically executive dysfunction, are well-established and en-
dorsed practices in professional societies, such as the American
Academy of Pediatrics, the American Academy of Neurology, and
the American Congress of Rehabilitation Medicine.122,123,142 The
guideline panel relied heavily on these well-established evidence-
based practices treatments of cognitive morbidities.
Summary of the evidence. The systematic review did not
identify any comparative studies in SCD that compared cognitive
rehabilitation to no rehabilitation. The review identified 1 randomized
controlled trial that compared academic tutoring with memory
rehabilitation vs academic tutoring, 1 observational study that
compared academic tutoring and specific learning and memory
strategies with academic tutoring, and 1 observational study
that compared computer-based cognitive training completers
with noncompleters. The evidence summary and EtD framework
can be found online at: https://guidelines.gradepro.org/profile/
c35a65914af486fba822a798f2059f64.
Rationale and expected benefits. Cognitive impairment in
SCD characteristically affect specific mental processes such as
memory, attention, executive function, processing speed, and
visual-spatial function. These deficits can impair one’s learning,
educational performance, work performance, medical adherence,
and activities of daily living. However, these deficits will not be
adequately identified without screening. Deficits in executive
function are commonly found in children and adults with SCD.6
These deficits correlate with the frequent injury to the frontal lobe, a
frequent area of the brain affected by silent cerebral infarcts.78,143
A systematic review of rehabilitation for impairment of executive
functions found a solid evidence base for interventions that
incorporate metacognitive strategy instruction that offers strategies
to solve problems, increase awareness, and cue for signals that may
improve problem solving and internal training. Most of the available
studies were conducted among adults with traumatic brain injury or
stroke.144 However, pilot studies that applied similar techniques to
children with SCD generated positive results.145 Cognitive lapses,
which occur most often in individuals with cognitive impairments,
and aspect of executive dysfunction (eg, defects in mental flexibility
and working memory) are the most common cause of poor
adherence to medical therapies in the general population.146-148
Functional assessments of executive function can both identify
deficits and inform interventions by determining what types of cues
patients need while completing multistep activities (Figure 3 in
supplemental File 5).149,150 Once these deficits are diagnosed, inter-
ventions can be implemented (Figure 4 in supplemental File 5).142
The intervention that makes the largest difference is the Cognitive
Orientation to Daily Occupational Performance (CO-OP),151 a top-
down approach that reduces impairments and improves health.
“Developed for use with children who have occupational perfor-
mance deficits, CO-OP is an individualized, client-centered approach
focused on strategy-based skill acquisition” through a process of
strategy use and guided discovery.122 CO-OP focuses treatments
directly on improving performance in everyday life activity rather
than treating the underlying impairments and hoping for sec-
ondary improvement in meaningful activities. Three randomized
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controlled trials have demonstrated that CO-OP is more effec-
tive than impairment-focused therapy delivered by occupational
therapists.152-154
Failure to identify and address cognitive impairments contributes
to difficulties with medical adherence. Formal assessments of
cognition providing an objective evaluation of the patient’s
cognitive capacities are often requested after cerebral injury is
diagnosed by cerebral MRI scan. The assessment enables health
care staff and the family to better understand the patient’s need
for information, support, and rehabilitation. The identification of
neurocognitive impairments is an important first step in obtaining
rehabilitation therapy121 and is recommended by national organiza-
tions representing several relevant disciplines.129 In addition, hema-
tologists and other medical providers can make use of behavioral
and family supports (eg, CO-OP approaches) to better support
adherence.129,148,155
Summary of harms and burden. No harm is anticipated after
providing cognitive rehabilitation. The panel did not identify
any burden with cognitive rehabilitation. Rather, a commitment to
time with occupational therapists is required for patients to receive
appropriate services. Working with the occupational therapist for
individuals with cognitive impairment requires a shift in the approach
to treatment of both providers and individuals with the disease to
increase awareness of cognitive impairments and to offer cognitive
rehabilitation therapies. Individuals with SCD should be treated in a
manner similar to that used for the thousands of individuals without
SCD, but with brain injury due to stroke or trauma.
EtD criteria and implementation considerations. The
quality of evidence on the benefits of cognitive rehabilitation
specifically in individuals with SCD was low. Hence, the panel
formulated recommendations advising clinicians to follow disease-
specific evidence-based guidelines for conditions identified through
screening. The certainty of the net benefit of this recommendation
was considered high. In addition, despite the lack of published
literature, input from patient representatives on the panel supported
the acceptability of cognitive rehabilitation therapy. Resources are
likely more available in academic centers with expertise in SCD.
The American Congress of Rehabilitation Medicine endorses
behavioral strategies to support individuals with executive function
impairments. Executive functions are a set of processes that focus
on managing oneself and one’s resources in order to achieve a goal,
involving mental control and self-regulation.121 After recognizing
executive dysfunction, the person can be trained to use task-
specific approaches, problem-solving strategies, external cues, and
internalized strategies.156
Systematic reviews of randomized controlled trials support the use
of goal-management training, problem-solving techniques, and time
pressure management.156,157 Challenges with following through on
plans of daily life that include medical appointments, medications,
education, and work are frequently underappreciated as cognitive
impairments. Unfortunately, those around the affected individuals
may label such impairments as problem behaviors or lack of
motivation. Similarly, the affected individual may be unaware of
these limitations as well. Despite endorsement from multiple
different professional societies, implementing cognitive-screening
strategies in high-risk children and adults with SCD will be
challenging to implement without basic research strategies to
identify barriers and facilitators within SCD care centers.
Research needs. The panel identified the following additional
areas in need of research.
1. Testing of specific cognitive rehabilitation strategies for people
with SCD is needed.
2. The optimal setting for cognitive rehabilitation therapy should be
identified.
3. The individuals most likely to benefit from cognitive rehabilitation
therapy should be identified.
Should screening with MRI for silent cerebral infarcts vs no
screening be used for children and adults with HbSS or HbSb0
thalassemia?
Recommendation 10.1
Given the high prevalence of silent cerebral infarcts in children
with HbSS or HbSb0 thalassemia (1 in 3) and their association
with cognitive impairment, poor school performance, and future
cerebral infarcts, the ASH guideline panel recommends at least a
1-time MRI screening, without sedation, to detect silent cerebral
infarcts in early-school-age children, when MRI can commonly be
performed without sedation (strong recommendation based on
moderate certainty in the evidence about effects ÅÅÅ◯).
Recommendation 10.2
Given the high prevalence of silent cerebral infarcts in adults
with HbSS or HbSb0 thalassemia and their association with
cognitive impairment, poor school performance, and future
cerebral infarcts, the ASH guideline panel suggests at least a
1-time MRI screening without sedation to detect silent cerebral
infarcts in these adults (conditional recommendation based on
low certainty in the evidence about effects ÅÅ◯◯).
Remarks:
1. The definition of a silent cerebral infarct–like lesion is an
MRI signal abnormality at least 3 mm in 1 dimension and visible
in 2 planes on fluid-attenuated inversion recovery (FLAIR) or T2-
weighted images (or similar image with 3-dimensional [3D]
imaging) with no correlative neurological findings.
2. After an infarct-like lesion is identified, the panel
recommends the following plan of action:
a. Neurological evaluation to assure that infarcts are
classified as a silent cerebral infarct rather than overt
stroke.
b. After a silent cerebral infarct is detected, there
should be a discussion regarding:
i. Secondary prevention options including regular
blood transfusions and HSCT.
ii. Cognitive screening assessment, as per recom-
mendation 8.
c. MRI surveillance every 12 to 24 months to assess
for cerebral infarct progression. If new infarcts are
present, then a discussion with the patient and
family regarding the pros and cons of a step-up in
therapy intensity to prevent cerebral infarct re-
currence.
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Specific background. Silent cerebral infarcts are common in
children and adults with HbSS or HbSb0 thalassemia, with a
prevalence of ;39%3 and ;50%, respectively (Figure 2)4 An
individual with SCD is diagnosed as having a silent cerebral infarct if
the following 3 features are present: (1) no history of focal
neurologic deficits; (2) on an MRI of the brain, a T2-weighted image
with FLAIR signal abnormality that is at least 3 mm in 1 dimension
and that is visible in 2 planes (or similar image with 3D imaging); and
(3) a normal neurological examination, preferably conducted by a
neurologist, or an abnormality found on examination that could not
be explained by the location of the brain lesion or lesions.25
1. This definition of silent cerebral infarct in children has been
validated. A definition of silent cerebral infarcts that requires a 5-mm
size with corresponding T1-weighted hypointensity on MRI, instead
of 3-mm only, will lead to a large misclassification bias with fewer
children being identified with silent cerebral infarcts.158 A minimum
size for silent cerebral infarct of 3 mm has been used in adult SCD
studies and is predictive of infarct recurrence (Figure 8).26
2. The diagnosis of a silent cerebral infarct can be challenging if
the radiologist is unfamiliar with the definition of silent cerebral
infarct in SCD. The definition of silent cerebral infarct cannot be
extrapolated to include the common definition of lacunar strokes
in the general population,143 which includes a T1 hypointensity
in addition to a 5-mm FLAIR hyperintensity.158
3. When available, the imaging should be done on a 3.0 T magnet
instead of a 1.5 T to improve the detection of silent cerebral
infarcts (Figure 8). As new FLAIR sequences are acquired via
whole-brain 3D imaging with no gaps between slices, the
requirement for imaging in 2 planes to confirm a silent infarct
may not be necessary.
4. Imaging examples of silent cerebral infarcts andmimics, specifically,
Virchow-Robin spaces and periventricular leukomalacia, which may
be useful for a clinician are displayed in Figure 8.
5. The Silent Cerebral Infarct Transfusion (SIT) Trial demonstrated
that blood transfusion therapy is superior to observation for
secondary stroke prevention (overt or silent cerebral infarct with
a 56% RR reduction in cerebral infarct recurrence).25 However,
the number needed to treat to prevent infarct recurrence with
regular blood transfusions is 13. There are no controlled trial
data demonstrating the noninferiority of hydroxyurea therapy to
regular blood transfusion therapy for children or adults with
silent cerebral infarcts.
Given the association with progressive cerebral infarcts (overt or
silent), the guideline panel recommends that students with HbSS or
HbSb0 thalassemia be screened with an unsedated MRI scan of the
brain at least once for silent cerebral infarcts with an MRI of the
brain without sedation. The panel recommended that adults with
HbSS or HbSb0 thalassemia be screened at least once for silent
cerebral infarcts even though there is no evidence for secondary
prevention of silent cerebral infarcts in the adult age group. The
panel, particularly the 2 non–health care provider representatives,
placed a significant value on knowing that a silent cerebral infarct
had occurred so that the affected child and adult will have a
potential explanation for cognitive impairment and can be informed
about a higher risk for infarct recurrence. Furthermore, once a silent
cerebral infarct is detected, the affected individual can be
monitored for infarct recurrence so that either regular blood
transfusion therapy25 or experimental treatment options can be
considered. These experimental therapies include, but are not
limited to, HSCT and gene therapy in children and adults.
Summary of the evidence. The systematic review did not identify
eligible studies that compared screening by means of MRI scan of the
brain to no screening. The review identified 15 studies that reported the
yield of screening, a study that showed the cumulative prevalence of
silent cerebral infarct in children, and 1 randomized controlled trial that
showed the benefit of regular blood transfusion therapy vs observation
in decreasing cerebral infarct recurrence in children with HbSS or
HbSb0 thalassemia who underwent MRI of the brain without sedation
and were noted to have silent cerebral infarcts.
The evidence summary and EtD framework can be found online at:
https://guidelines.gradepro.org/profile/e53297aadb1f5346b6de0
d64eebccacf.
Rationale and expected benefits. There are 5 independent
reasons to justify screening for silent cerebral infarct in children and
adults with HbSS or HbSb0 thalassemia:
1. Silent cerebral infarcts are prevalent; ;39% of children3 and
50% of young adults will have a silent cerebral infarct.4
2. Silent cerebral infarcts are progressive in both children25,159
and adults26,27 (Figure 9A-B, respectively). The presence of
silent cerebral infarcts predicts future neurological injury to
the brain with an incidence rate that exceeds the accepted
threshold for prevention of neurological injury in adults with
atrial fibrillation not receiving anticoagulation.
3. Silent cerebral infarcts are associated with at least a 5-point
FSIQ drop in children,134 and biologically plausible evidence to
believe a similar degree of neurological morbidity in adults.
4. Once silent cerebral infarcts are identified, children and adults
are eligible for evaluation for individual education plans and
Americans with Disability Act services, respectively.
5. Most silent cerebral infarcts occur in the border zone regions of
the brain, including in the frontal lobe,72 which disproportion-
ately affect executive function. The American Congress of
Rehabilitation Medicine has formally endorsed evidence-based
strategies to support individuals with executive dysfunction.
6. Children with silent cerebral infarcts can be treated with regular
blood transfusion to substantially reduce the incidence of a new
stroke, silent infarct recurrence, or both.25
Summary of harms and burden. The summary of harms and
burden is the same as for PICO questions #1 and #2 (see Table 1). The
potential harms associated with regular blood transfusion therapy have
been quantified in controlled clinical trials for primary and secondary
prevention strokes in children with HbSS or HbSb0 thalassemia.
These adverse events include, but are not limited to, the
following, in decreasing order of prevalence: excessive iron
stores62,63,90 that may eventually require chelation therapy,75 red
blood cell alloimmunization,11,25,65 and adverse blood trans-
fusion reactions.64,75 The burden of indefinite regular blood trans-
fusion therapy is significant for the family. Typically, the regular blood
transfusion occurs monthly and often requires 2 visits (the first for
crossmatching of the red blood cell units and the second for the
actual blood transfusion).We did not find a study rating the intangible
challenges of regular blood transfusion therapy for families, but the
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panel, including the 2 patient representatives, believed strongly
that family preferences and the inconvenience and financial
resources associated with regular blood transfusion therapy
should be considered. Despite the burden, the panel believed
that both children and adults should be aware of whether they
have a silent cerebral infarct, an injury to the brain that places
the individual at risk for future cerebral infarcts and may impact
educational attainment in children and adults, as well as
employment and family support in adults.
EtD criteria and implementation considerations. Access to
MRI may be limited in some geographic areas or low-middle-
income settings. Cost-effectiveness data are unavailable, but can
be extrapolated from other environmental exposures associated
with neurologic sequelae, low IQ, and social outcomes.
A hematologist’s diagnosis of only silent cerebral infarct in a child
with HbSS or HbSb0 thalassemia will misclassify ;7% of the
children as having a silent cerebral infarct, when in fact they had
a stroke.25 This misclassification of a stroke as a silent cerebral
infarct may result in a different clinical course in treated and
untreated individuals. In the presence of a silent cerebral infarct,
annual surveillance with MRI may allow for increased therapeutic
interventions; thus, a second screening MRI can be considered
if new or cognitive impairment occurs or a change in academic
performance is noted. A child who cannot undergo an MRI
without sedation may be supported by child life services to
attempt MRI without sedation.
Given that children and adults with HbSS or HbSb0 thalassemia
have an increased prevalence of intracranial160 and extracranial3
vasculopathy and surgically correctable aneurysms,4,161 MRA of
the intracranial and extracranial vessels should be added to the MRI
of the brain.
Research needs. The panel identified the following additional
areas in need of research.
1. A therapeutic strategy for primary prevention of silent cerebral
infarcts is needed.
BA
Axial T2-weighted Axial FLAIR
Axial FLAIR Axial FLAIR
Axial T2-weightedAxial FLAIR Axial T1-weightedCoronal FLAIR
Axial FLAIR
Axial FLAIR
Axial FLAIR D
Axial T2-weightedAxial FLAIRE F
C
1.5 Tesla 3.0 Tesla
Figure 8. SCI and mimics in SCD. (A) Axial (left) and coronal fluid-attenuated inversion recovery (FLAIR) images illustrate a qualifying silent cerebral infarct in the left parietal
lobe (white arrows). An infarct-like lesion was defined as an MRI signal abnormality that was at least 3 mm in 1 dimension and that was visible in 2 planes on FLAIR images or
similar image with 3D FLAIR sequence (not shown) and documented neurological examination performed by a neurologist demonstrating that the participant has a normal
neurologic examination or an abnormality on examination that could not be explained by the location of the brain lesion(s). (B) Axial FLAIR (left), T2-weighted (middle), and
T1-weighted (right) images of the same lesion demonstrate that the FLAIR sequence is better for the identification of SCIs (green circles). (C) Axial FLAIR images show that
higher magnet strength (3.0 Tesla) improves image quality and identification of subtle lesions only seen at 3.0 Tesla (arrowhead). More obvious lesions are visible at 1.5 Tesla
and 3.0 Tesla (arrows). (D) Linear and punctate T2 hyperintensities that suppress on FLAIR are consistent with prominent perivascular spaces (Virchow-Robin spaces).
(E) Terminal zones of myelination on T2-weighted images. Axial FLAIR and T2-weighted images show ill-defined symmetrical T2-weighted hyperintensity in the deep parietal
white matter. The T2-weighted image on the right illustrates that there are well-defined linear perivascular spaces extending throughout the area of subtle hyperintensity
(green arrows). (F) Axial FLAIR images demonstrate a case of white matter injury in a premature infant (periventricular leukomalacia) that can mimic a SCI because of the
increased signal on FLAIR (white arrows).
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2. Imaging strategies to identify subgroups of children and adults
likely to have infarct recurrence are needed.
3. Alternative treatment strategies, other than regular blood trans-
fusion, for secondary prevention of infarct recurrence in children
and adults with silent cerebral infarcts should be developed.
4. The clinical benefit of HSCT or gene therapy vs regular blood
transfusion therapy for secondary prevention of cerebral infarcts
in children and adults with preexisting silent cerebral infarct
should be determined.
5. The optimal treatment and infarct recurrence rate for children
and adults with SCD phenotypes other than HbSS or HbSb0
thalassemia, and with silent cerebral infarcts should be determined.
6. The clinical utility of screening for silent cerebral infarcts in low-
middle–income settings withMRI scans is unknown. Furthermore,
the neuroradiology expertise is far less available. If feasible,
screening for silent cerebral infarcts in children and adults with
HbSS in a low-middle–income country should be done for the
same reason that the screening occurs in high-income settings.
What are others saying and what is new in
these ASH guidelines?
SCD is a rare disease, with few guidelines developed for prevention,
screening, and treatment of CNS manifestations in children and
adults with SCD. For only 2 of 10 PICO questions did we have the
benefit of phase 3 randomized controlled trials on which to base our
recommendations: screening and treatment of primary stroke pre-
vention (with TCD) and screening and treatment of silent cerebral
infarct to prevent cerebral infarct recurrence. The responses to the
remaining PICO questions were based on review of all available
observational studies, including cerebral hemodynamic studies in SCD.
With the exception of primary and secondary stroke prevention,
guidelines for management of common CNS problems in SCD were
Figure 9. Preexisting SCIs. (A) Preexisting SCIs associated with
subsequent neurological events in children with HbSS or HbSb0
thalassemia. Time to first neurological event-stroke, seizure, TIA for
children with normal or conditional TCD measurements (time averaged
mean maximum velocity of ,200 cm/s, nonimaging, or ,185 cm/s
imaging technique) and with (n 5 68) and without SCIs on MRI
(n 5 353). (B) Associated with recurrent SCIs in adults with sickle cell
anemia. A total of 54 adults with HbSS or HbSb0 thalassemia had a
minimum time of 6 months between at least 2 MRIs of the brain; in this
group of adults, 43% (n 5 23) had SCI at baseline and 57% (n 5 31)
had no SCI at baseline; individuals with overt stroke were excluded
based on history and examination by a neurologist. Reprinted from
Jordan et al159 (A) and Jordan et al26 (B) with permission.
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not discussed in the 2014 NHLBI Expert Panel Report on the
Evidence-Based Management of Sickle Cell Disease. The SIT
Trial25 was published after the 2014 panel review and was not
referenced in the 2014 NHLBI Expert Panel Report.162 The recent
AHA/ASA statement on pediatric stroke management86 provides
guidance for initial management of suspected or confirmed acute
ischemic strokes in children with SCD, as well as primary and
secondary stroke prevention with regular blood transfusion. Their
recommendations are similar to the ASHCNS panel recommendation.
For children and adults with SCD presenting with a focal neurological
deficit, the panel recommends increasing the hemoglobin level with a red
blood cell transfusion to achieve the goal of improving oxygen delivery to
the brain. Given the challenge of distinguishing between MRI diffusion-
weighted negative ischemic strokes and TIAs,163 the clinical decision to
manage an individual with SCD and a suspected ischemic infarct should
not be based solely on the results of the MRI, but rather should be a
bedside decision where the risks and benefits of transfusion must be
considered. In most cases, the benefit of transfusing a child or adult with
SCD and with acute focal neurologic deficits will outweigh the risks.
The panel did not include the role of HSCT for primary and secondary
stroke prevention, an emerging treatment strategy in high-income
settings. The panel’s absence of any recommendation for HSCT for
primary stroke prevention or secondary prevention of infarct recurrence
does not reflect an absence of data or priority for the panel, but rather a
decision to defer this subject matter to the ASHHSCTGuideline Panel.
The panel members determined that there was sufficient evidence
to support guidelines for initial screening and subsequent
surveillance for developmental delays and cognitive impairment
for the general population, where the prevalence of impairments is
significantly lower than in children and adults with SCD, to be
applied to individuals with SCD. The panel’s strong recommenda-
tion for screening for developmental delay and cognitive impairment
in children with SCD was based on 3 factors. First, the American
Academy of Pediatrics recommends that all children be screened
for both developmental delay and cognitive impairment122; second,
children with SCD have a high prevalence of these impairments;
and third, there is high impact for securing educational resources
for children with significant impairments via individualized education
plans. Similarly, the ASH guideline panel’s conditional recommen-
dation for screening for cognitive impairment in adults with SCD
was based on at least 2 dominant factors. The first was the
recommendation by the American Academy of Neurology for
screening for mild cognitive impairment in adults123; the second
was the high prevalence of these impairments in adults with SCD.6
Research in implementation science is required to define the
optimal reach (proportion of individuals that receive screening and
ongoing surveillance) for detecting developmental delay and
cognitive impairment in SCD. The ASH Guideline Panel endorsed
the evidence-based recommendations by the American Congress
of Rehabilitation Medicine for cognitive rehabilitation.121
Revision or adaptation of the guidelines
Plans for updating these guidelines
After publication of these guidelines, ASH will maintain them
through surveillance for new evidence, ongoing review by experts,
and regular revisions.
Updating or adapting recommendations locally
Adaptation of these guidelines will be necessary in many circum-
stances. These adaptations should be based on the associated EtD
frameworks.164
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